LA JOLLA INSTITUTE FOR IMMUNOLOGY
Reduce your risk when donating: see where the money actually goes.
Reduce your risk when donating: see where the money actually goes.
Cite this
Plain text LA JOLLA INSTITUTE FOR IMMUNOLOGY. furp.org, nonprofit organization profile, tax years 2010–2024. https://furp.org/org/la-jolla-institute-for-immunology-330328688. Retrieved 2026-11-12.
APA furp.org. (n.d.). LA JOLLA INSTITUTE FOR IMMUNOLOGY [Nonprofit organization profile; tax years 2010–2024]. Retrieved November 12, 2026, from https://furp.org/org/la-jolla-institute-for-immunology-330328688
MLA “LA JOLLA INSTITUTE FOR IMMUNOLOGY.” furp.org, tax years 2010–2024, https://furp.org/org/la-jolla-institute-for-immunology-330328688. Accessed 12 Nov. 2026.
Retrieved 2026-11-12; covers tax years 2010–2024. Data: furp.org (index © the FURP Alliance; the records are public domain).
2024 · Form 990 · revenue $84.2M · expenses $86.0M · assets $62.5M
- Also known as
- CENTER FOR AUTOIMMUNITY AND INFLAMMATION
- EIN
- 33-0328688
- Address
- 9240 ATHENA CIRCLE, LA JOLLA, CA 92037-0000
- Website
- WWW.LJI.ORG
- NTEE code
- H99 Medical Research N.E.C. (Medical Research) inferred (by a small language model from the name and 990 text, confidence 0.85; not an IRS classification)
- FURP topic
- science: research education · women: issues (from its 990 text; the topic index)
- Exempt type
- 501(c)(3): charitable, religious, educational, scientific or literary (corporation)
- Ruling date
- September 1989 (when the IRS recognized its exemption)
- IRS status
- Exempt (unconditional) (IRS Business Master File) IRS data ↗
- Tax-deductible donations
- Yes: listed in IRS Publication 78 (public charity) Pub 78 ↗
- Foundation status
- Hospital or medical research organization
- Cross-check
- ProPublica Nonprofit Explorer
Mission
AT LA JOLLA INSTITUTE FOR IMMUNOLOGY, OUR SCIENTISTS FOCUS ON UNDERSTANDING HOW THE IMMUNE SYSTEM WORKS IN ORDER TO PROMOTE HUMAN HEALTH AND PREVENT DISEASE. OUR DISCOVERIES APPLY TO MANY DISEASES, RANGING FROM DIABETES TO HEART DISEASE, INFECTIOUS DISEASES TO CANCER.
Each tax year counts once: when a return was amended, only the latest return for that period is used below (superseded returns stay listed, greyed, under Finances).
People paid by the organization
29 people paid across every filing: current people first, then by total pay from this organization. Organizations counts every nonprofit each person appears on.
| Name | Latest title | Years | Latest year pay | Total pay from here | Organizations |
|---|---|---|---|---|---|
| Mitchell Kronenberg | DIR/PRES EMERITUS/PROFESSOR | 2010-2024 | $317,985 | $7,326,363 | 3 |
| Alessandro Sette | DIVISION HEAD/CENTER HEAD/PROF | 2010-2024 | $701,760 | $7,248,527 | 1 |
| Stephen P Schoenberger | PROFESSOR | 2010-2024 | $406,064 | $4,054,096 | 1 |
| Erica Saphire | PRESIDENT & CEO | 2020-2024 | $897,346 | $3,747,689 | 1 |
| Hilde Cheroutre | DIVISION HEAD/PROFESSOR | 2012-2024 | $383,527 | $2,974,912 | 3 |
| Michael Croft | DIRECTOR, ACADEMIC AFFAIRS | 2019-2024 | $465,672 | $2,754,367 | 1 |
| Shane Crotty | CHIEF SCIENTIFIC OFFICER | 2021-2024 | $507,560 | $1,860,088 | 1 |
| Richard Stryjewski | CFO & TREASURER | 2021-2024 | $385,593 | $1,087,732 | 1 |
| Bjoern Peters | PROFESSOR | 2023-2024 | $490,255 | $944,745 | 1 |
| John Keegan | COO | 2023-2024 | $366,949 | $732,963 | 1 |
| Margaret Ng Thow Hing | SECRETARY & CHIEF LEGAL OFFICER | 2024 | $351,978 | $351,978 | 1 |
| Linda Sherman | DIRECTOR | 2022-2024 | $0 | $7,500 | 2 |
| Klaus Ley (former) | DIVISION HEAD/PROFESSOR | 2010-2021 | $383,007 | $3,987,070 | 1 |
| Stephen Wilson (former) | EVP, COO & CTO (END 04/21) | 2010-2021 | $240,393 | $3,800,937 | 1 |
| Amnon Altman (former) | Director, Scientific Affairs | 2010-2017 | $385,299 | $2,961,892 | 1 |
| Joel Linden (former) | Professor | 2010-2016 | $342,995 | $2,263,928 | 1 |
| Charles Carpowich (former) | EVP/COO/CFO THROUGH 11/21/2013 | 2010-2014 | $323,783 | $1,800,109 | 1 |
| Catherine Hedrick (former) | PROFESSOR | 2017-2021 | $401,388 | $1,565,213 | 1 |
| Anjana Rao (former) | DIVISION HEAD/PROFESSOR | 2011-2014 | $367,321 | $1,380,499 | 1 |
| Jennifer K Keyes (former) | CFO (End 06/18/2019) | 2014-2019 | $237,072 | $884,558 | 1 |
| Michael Dollar (former) | CFO/TREASURER/SECRETARY (END 04/21) | 2019-2021 | $152,011 | $643,873 | 1 |
| Maryann Stewart (former) | FORMER VP CHIEF DEV. OFFICER | 2010-2012 | $130,744 | $565,381 | 1 |
| Joel Martin (former) | MANAGING DIRECTOR, CBO (END 12/22) | 2022 | $446,193 | $446,193 | 1 |
| Douglas Henson (former) | CONTROLLER/INTERIM CFO (END 11/21) | 2021 | $241,854 | $241,854 | 1 |
| Carl Ware (former) | DIVISION HEAD/MEMBER | 2010 | $217,359 | $217,359 | 1 |
| Tai Nguyen (former) | CFO THROUGH 08/18/2014 | 2014 | $216,273 | $216,273 | 1 |
| Samuel Strober Md (former) | FORMER DIRECTOR | 2010-2013 | $0 | $13,500 | 1 |
| Susan Swain Phd (former) | DIRECTOR | 2010 | $5,500 | $5,500 | 1 |
| David A Brenner Md (former) | DIRECTOR (END 06/22) | 2016-2022 | $2,500 | $5,000 | 4 |
Officers and directors, no compensation reported
64 people listed on the returns with $0 (or no amount) in every compensation column: current people first. Hours are as filed on the latest return each person appears on.
| Name | Latest title | Years | Hrs/wk (latest) | Compensation | Organizations |
|---|---|---|---|---|---|
| David R Webb | DIRECTOR | 2011-2024 | 2 | $0 reported | 3 |
| Anthony R Carr | DIRECTOR | 2013-2024 | 2 | $0 reported | 1 |
| Barbara Donnell | DIRECTOR | 2022-2024 | 2 | $0 reported | 1 |
| Brad Greenwald | DIRECTOR (START 05/03/2024) | 2024 | 2 | $0 reported | 1 |
| Carolee Lee | DIRECTOR | 2021-2024 | 2 | $0 reported | 1 |
| David M Rickey | DIRECTOR | 2020-2024 | 2 | $0 reported | 1 |
| Emily Holmes | DIRECTOR | 2022-2024 | 2 | $0 reported | 1 |
| Francois Ferre | DIRECTOR(BEG 03/24)/CHAIR(BEG 10/24) | 2017-2024 | 2 | $0 reported | 1 |
| Fred Miller | DIRECTOR | 2022-2024 | 2 | $0 reported | 1 |
| Gail K Naughton | CHAIR (TERM 09/30/24) & DIRECTOR | 2012-2024 | 2 | $0 reported | 1 |
| Genevieve T Jacobs | DIRECTOR (TERM 03/07/2024) | 2021-2024 | 2 | $0 reported | 1 |
| John M Carethers | DIRECTOR (EX-OFFICIO) | 2023-2024 | 2 | $0 reported | 1 |
| Mark V Bowles | DIRECTOR | 2016-2024 | 2 | $0 reported | 1 |
| Paul Thiel | DIRECTOR | 2019-2024 | 2 | $0 reported | 1 |
| Renetta Haas | DIRECTOR | 2023-2024 | 2 | $0 reported | 1 |
| Richard S Bodman | DIRECTOR | 2015-2024 | 2 | $0 reported | 1 |
| Robert C Dynes | DIRECTOR | 2010-2024 | 2 | $0 reported | 1 |
| Sandor W Shapery | DIRECTOR (TERM 05/03/2024) | 2019-2024 | 2 | $0 reported | 1 |
| Sandra Schmid | DIRECTOR | 2022-2024 | 2 | $0 reported | 1 |
| Sandy Boek Werness | DIRECTOR (START 09/13/2024) | 2024 | 2 | $0 reported | 1 |
| Susan Davis | DIRECTOR | 2022-2024 | 2 | $0 reported | 1 |
| Thomas L Tullie | DIRECTOR | 2016-2024 | 2 | $0 reported | 1 |
| Yoshifumi Torii | DIRECTOR (EX-OFFICIO) | 2022-2024 | 2 | $0 reported | 1 |
| J Mark Waxman (former) | DIRECTOR (END 02/23) | 2020-2023 | 2 | $0 reported | 1 |
| Pamela K Wasserman (former) | DIRECTOR (END 12/23) | 2019-2023 | 2 | $0 reported | 1 |
| Barton J Cohen (former) | DIRECTOR (END 02/22) | 2016-2022 | 2 | $0 reported | 1 |
| Franois Ferr Phd (former) | DIRECTOR | 2020-2022 | 2 | $0 reported | 1 |
| Genevive T Jacobs (former) | DIRECTOR | 2019-2022 | 2 | $0 reported | 1 |
| Michael D Coit (former) | DIRECTOR (END 11/22) | 2016-2022 | 2 | $0 reported | 1 |
| Mitsuo Satoh Phd (former) | DIRECTOR (END 02/22) | 2019-2022 | 2 | $0 reported | 1 |
| Robert W Mahley Md Phd (former) | DIRECTOR (END 11/22) | 2016-2022 | 2 | $0 reported | 1 |
| David Dominguez (former) | DIRECTOR (END 05/21) | 2010-2021 | 2 | $0 reported | 1 |
| Eric V Zwisler (former) | DIRECTOR/CHAIR (END 11/21) | 2014-2021 | 2 | $0 reported | 1 |
| Hunt Pettit (former) | DIRECTOR (END 05/21) | 2015-2021 | 2 | $0 reported | 1 |
| Kristine Charton Jd (former) | DIRECTOR (END 11/21) | 2015-2021 | 2 | $0 reported | 1 |
| Larry S Spitcaufsky (former) | DIRECTOR (END 05/21) | 2015-2021 | 2 | $0 reported | 1 |
| Lynda Stuart Md Phd (former) | DIRECTOR (END 11/21) | 2019-2021 | 2 | $0 reported | 1 |
| Vanessa V Wertheim Phd (former) | Director (End 05/19/2020) | 2017-2020 | 2 | $0 reported | 3 |
| John E Major Chair (former) | Director (End 05/29/2020) | 2019-2020 | 2 | $0 reported | 1 |
| Franois Ferre PhD (former) | Director | 2019 | 2 | $0 reported | 1 |
| Pamela W Blakely (former) | Director | 2014-2017 | 2 | $0 reported | 1 |
| Sergio Jinich (former) | Director (End 04/03/2017) | 2013-2017 | 2 | $0 reported | 1 |
| Richard K Kornfeld (former) | Director | 2010-2017 | 2 | $0 reported | 1 |
| John E Major (former) | Director | 2010-2017 | 2 | $0 reported | 1 |
| Hiroshi Okazaki PhD (former) | Director | 2016-2017 | 2 | $0 reported | 1 |
| David L Steffy (former) | Director (Start 08/11/17) | 2017 | 2 | $0 reported | 1 |
| Fred Wasserman MBA DrPH (former) | Director | 2017 | 2 | $0 reported | 1 |
| Herbert A Wertheim OK DSC (former) | Director (End 05/19/17) | 2013-2017 | 2 | $0 reported | 1 |
| Leroy Hood MD PhD (former) | Director (end 7/29/16) | 2010-2016 | 2 | $0 reported | 1 |
| Toshifumi Mikayama PhD (former) | Director (end 2/13/16) | 2010-2016 | 2 | $0 reported | 1 |
| David A Perkins (former) | Director (end 4/4/16) | 2012-2016 | 2 | $0 reported | 1 |
| Rhonda F Rhyne (former) | Director (end 11/12/16) | 2010-2016 | 2 | $0 reported | 1 |
| Fred Wasserman DrPH (former) | Director | 2013-2016 | 2 | $0 reported | 1 |
| Tina S Nova Phd (former) | DIRECTOR (THROUGH 06/02/2015) | 2013-2015 | 2 | $0 reported | 9 |
| Gene W Ray Phd (former) | DIRECTOR (THROUGH 07/01/2015) | 2013-2015 | 2 | $0 reported | 1 |
| Timothy J Wollaeger (former) | DIRECTOR (THROUGH 11/15/2015) | 2013-2015 | 2 | $0 reported | 1 |
| Charles J Cashion (former) | DIRECTOR | 2012-2014 | 2 | $0 reported | 1 |
| Mark Fischer (former) | FORMER DIRECTOR | 2010-2012 | 2 | $0 reported | 1 |
| Michael Martin (former) | FORMER DIRECTOR | 2010-2012 | 2 | $0 reported | 1 |
| William Rohn (former) | FORMER DIRECTOR | 2010-2012 | 2 | $0 reported | 1 |
| Harold Buchanan (former) | DIRECTOR | 2010 | 2 | $0 reported | 1 |
| Katina Tsakopoulos (former) | DIRECTOR | 2010 | 2 | $0 reported | 1 |
| Kimishige Ishizaka Md Phd (former) | DIRECTOR/EMERITUS | 2010 | 2 | $0 reported | 1 |
| Steven Odre (former) | DIRECTOR | 2010 | 2 | $0 reported | 1 |
People by year
2024 · 35 people listed · 11 paid, $5.3M · 462 employees · 106 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ERICA SAPHIRE | PRESIDENT & CEO | 40 | $781,772 | $0 | $115,574 | $897,346 | 1 |
| ALESSANDRO SETTE | DIVISION HEAD/CENTER HEAD/PROF | 40 | $599,418 | $0 | $102,342 | $701,760 | 1 |
| SHANE CROTTY | CHIEF SCIENTIFIC OFFICER | 40 | $406,486 | $0 | $101,074 | $507,560 | 1 |
| BJOERN PETERS | PROFESSOR | 40 | $411,190 | $0 | $79,065 | $490,255 | 1 |
| MICHAEL CROFT | DIRECTOR, ACADEMIC AFFAIRS | 40 | $380,393 | $0 | $85,279 | $465,672 | 1 |
| STEPHEN P SCHOENBERGER | PROFESSOR | 40 | $330,131 | $0 | $75,933 | $406,064 | 1 |
| RICHARD STRYJEWSKI | CFO & TREASURER | 40 | $322,730 | $0 | $62,863 | $385,593 | 1 |
| HILDE CHEROUTRE | DIVISION HEAD/PROFESSOR | 40 | $323,087 | $0 | $60,440 | $383,527 | 3 |
| JOHN KEEGAN | COO | 40 | $298,588 | $0 | $68,361 | $366,949 | 1 |
| MARGARET NG THOW HING | SECRETARY & CHIEF LEGAL OFFICER | 40 | $292,248 | $0 | $59,730 | $351,978 | 1 |
| MITCHELL KRONENBERG | DIR/PRES EMERITUS/PROFESSOR | 40 | $262,000 | $0 | $55,985 | $317,985 | 3 |
| ANTHONY R CARR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| BARBARA DONNELL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| BRAD GREENWALD | DIRECTOR (START 05/03/2024) | 2 | $0 | $0 | $0 | $0 | 1 |
| CAROLEE LEE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID M RICKEY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID R WEBB | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| EMILY HOLMES | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| FRANCOIS FERRE | DIRECTOR(BEG 03/24)/CHAIR(BEG 10/24) | 2 | $0 | $0 | $0 | $0 | 1 |
| FRED MILLER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GAIL K NAUGHTON | CHAIR (TERM 09/30/24) & DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GENEVIEVE T JACOBS | DIRECTOR (TERM 03/07/2024) | 2 | $0 | $0 | $0 | $0 | 1 |
| JOHN M CARETHERS | DIRECTOR (EX-OFFICIO) | 2 | $0 | $0 | $0 | $0 | 1 |
| LINDA SHERMAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 2 |
| MARK V BOWLES | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| PAUL THIEL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RENETTA HAAS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD S BODMAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT C DYNES | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SANDOR W SHAPERY | DIRECTOR (TERM 05/03/2024) | 2 | $0 | $0 | $0 | $0 | 1 |
| SANDRA SCHMID | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SANDY BOEK WERNESS | DIRECTOR (START 09/13/2024) | 2 | $0 | $0 | $0 | $0 | 1 |
| SUSAN DAVIS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| THOMAS L TULLIE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| YOSHIFUMI TORII | DIRECTOR (EX-OFFICIO) | 2 | $0 | $0 | $0 | $0 | 1 |
2023 · 34 people listed · 11 paid, $5.0M · 464 employees · 107 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ERICA SAPHIRE | PRESIDENT & CEO | 40 | $784,780 | $0 | $110,210 | $894,990 | 1 |
| ALESSANDRO SETTE | DIVISION HEAD/CENTER HEAD/PROF | 40 | $557,795 | $0 | $103,396 | $661,191 | 1 |
| SHANE CROTTY | CHIEF SCI. OFFICER (START 09/23) | 40 | $409,436 | $0 | $87,509 | $496,945 | 1 |
| MITCHELL KRONENBERG | DIR. & CHIEF SCI. OFFICER(END 9/23) | 40 | $406,198 | $0 | $74,840 | $481,038 | 3 |
| MICHAEL CROFT | DIRECTOR, ACADEMIC AFFAIRS | 40 | $390,575 | $0 | $80,091 | $470,666 | 1 |
| BJOERN PETERS | PROFESSOR | 40 | $378,202 | $0 | $76,288 | $454,490 | 1 |
| STEPHEN P SCHOENBERGER | PROFESSOR | 40 | $320,610 | $0 | $85,226 | $405,836 | 1 |
| HILDE CHEROUTRE | DIVISION HEAD/PROFESSOR | 40 | $323,988 | $0 | $59,766 | $383,754 | 3 |
| JOHN KEEGAN | COO | 40 | $298,258 | $0 | $67,756 | $366,014 | 1 |
| RICHARD STRYJEWSKI | CFO, TREASURER AND SECRETARY | 40 | $302,026 | $0 | $61,068 | $363,094 | 1 |
| LINDA SHERMAN | DIRECTOR | 2 | $5,000 | $0 | $0 | $5,000 | 2 |
| ANTHONY R CARR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| BARBARA DONNELL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| CAROLEE LEE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID M RICKEY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID R WEBB | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| EMILY HOLMES | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| FRANCOIS FERRE | DIRECTOR (END 02/23) | 2 | $0 | $0 | $0 | $0 | 1 |
| FRED MILLER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GAIL K NAUGHTON | DIRECTOR, CHAIRMAN | 2 | $0 | $0 | $0 | $0 | 1 |
| GENEVIEVE T JACOBS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| J MARK WAXMAN | DIRECTOR (END 02/23) | 2 | $0 | $0 | $0 | $0 | 1 |
| JOHN M CARETHERS | DIRECTOR (START 02/23) | 2 | $0 | $0 | $0 | $0 | 1 |
| MARK V BOWLES | DIRECTOR (START 09/23) | 2 | $0 | $0 | $0 | $0 | 1 |
| PAMELA K WASSERMAN | DIRECTOR (END 12/23) | 2 | $0 | $0 | $0 | $0 | 1 |
| PAUL THIEL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RENETTA HAAS | DIRECTOR (START 12/23) | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD S BODMAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT C DYNES | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SANDOR W SHAPERY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SANDRA SCHMID | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SUSAN DAVIS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| THOMAS L TULLIE | DIRECTOR (START 09/23) | 2 | $0 | $0 | $0 | $0 | 1 |
| YOSHIFUMI TORII | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
2022 · 35 people listed · 10 paid, $4.7M · 515 employees · 151 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ALESSANDRO SETTE | DIVISION HEAD/CENTER HEAD/PROF | 40 | $800,014 | $0 | $109,069 | $909,083 | 1 |
| ERICA SAPHIRE | PRESIDENT & CEO | 40 | $796,838 | $0 | $104,588 | $901,426 | 1 |
| MITCHELL KRONENBERG | CHIEF SCIENTIFIC OFFICER | 40 | $564,853 | $0 | $80,893 | $645,746 | 3 |
| MICHAEL CROFT | DIRECTOR, ACADEMIC AFFAIRS | 40 | $512,924 | $0 | $76,837 | $589,761 | 1 |
| SHANE CROTTY | PROFESSOR | 40 | $367,380 | $0 | $80,693 | $448,073 | 1 |
| JOEL MARTIN | MANAGING DIRECTOR, CBO (END 12/22) | 40 | $421,434 | $0 | $24,759 | $446,193 | 1 |
| STEPHEN P SCHOENBERGER | PROFESSOR | 40 | $336,305 | $0 | $85,204 | $421,509 | 1 |
| RICHARD STRYJEWSKI | CFO, TREASURER, & SECRETARY | 40 | $271,052 | $0 | $21,166 | $292,218 | 1 |
| DAVID A BRENNER MD | DIRECTOR (END 06/22) | 2 | $0 | $0 | $2,500 | $2,500 | 4 |
| LINDA SHERMAN PHD | DIRECTOR (START 11/22) | 2 | $0 | $0 | $2,500 | $2,500 | 2 |
| ANTHONY CARR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| BARBARA DONNELL | DIRECTOR (START 11/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| BARTON J COHEN | DIRECTOR (END 02/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| CAROLEE LEE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID M RICKEY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID R WEBB PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| EMILY HOLMES ESQ PHD | DIRECTOR (START 06/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| FRANOIS FERR PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| FRED MILLER | DIRECTOR (START 08/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| GAIL K NAUGHTON PHD | DIRECTOR, CHAIR | 2 | $0 | $0 | $0 | $0 | 1 |
| GENEVIVE T JACOBS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| J MARK WAXMAN JD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| MARK V BOWLES | DIRECTOR (END 02/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| MICHAEL D COIT | DIRECTOR (END 11/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| MITSUO SATOH PHD | DIRECTOR (END 02/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| PAMELA K WASSERMAN MPH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| PAUL THIEL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD S BODMAN | DIRECTOR (START 08/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT C DYNES PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT W MAHLEY MD PHD | DIRECTOR (END 11/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| SANDOR W SHAPERY JD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SANDRA SCHMID PHD | DIRECTOR (START 11/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| SUSAN DAVIS MSW | DIRECTOR (START 11/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| THOMAS L TULLIE | DIRECTOR (END 08/22) | 2 | $0 | $0 | $0 | $0 | 1 |
| YOSHIFUMI TORII PHD | DIRECTOR (START 06/22) | 2 | $0 | $0 | $0 | $0 | 1 |
2021 · 38 people listed · 13 paid, $4.7M · 501 employees · 111 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ALESSANDRO SETTE | DIVISION HEAD/CENTER HEAD/PROF | 40 | $609,542 | $0 | $98,167 | $707,709 | 1 |
| MITCHELL KRONENBERG | CSO (START 09/21)/PRES. (END 09/21) | 40 | $573,510 | $0 | $77,643 | $651,153 | 3 |
| ERICA SAPHIRE | PRESIDENT & CEO (START 09/21) | 40 | $509,960 | $0 | $89,182 | $599,142 | 1 |
| MICHAEL CROFT | DIVISION HEAD/PROFESSOR (END 09/21) | 40 | $352,146 | $0 | $74,975 | $427,121 | 1 |
| SHANE CROTTY | PROFESSOR | 40 | $331,820 | $0 | $75,690 | $407,510 | 1 |
| STEPHEN P SCHOENBERGER | PROFESSOR | 40 | $318,131 | $0 | $83,585 | $401,716 | 1 |
| CATHERINE HEDRICK | PROFESSOR | 40 | $331,005 | $0 | $70,383 | $401,388 | 1 |
| KLAUS LEY | DIVISION HEAD/PROFESSOR | 40 | $323,227 | $0 | $59,780 | $383,007 | 1 |
| DOUGLAS HENSON | CONTROLLER/INTERIM CFO (END 11/21) | 40 | $217,621 | $0 | $24,233 | $241,854 | 1 |
| STEPHEN WILSON | EVP, COO & CTO (END 04/21) | 40 | $208,041 | $0 | $32,352 | $240,393 | 1 |
| MICHAEL DOLLAR | CFO/TREASURER/SECRETARY (END 04/21) | 40 | $130,085 | $0 | $21,926 | $152,011 | 1 |
| RICHARD STRYJEWSKI | CFO/TREASURER/SECRETARY (START 10/21) | 40 | $45,175 | $0 | $1,652 | $46,827 | 1 |
| DAVID A BRENNER MD | DIRECTOR | 2 | $2,500 | $0 | $0 | $2,500 | 4 |
| ANTHONY CARR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| BARTON J COHEN | DIRECTOR (END 02/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| CAROLEE LEE | DIRECTOR (START 05/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOMINGUEZ | DIRECTOR (END 05/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID M RICKEY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID R WEBB PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| ERIC V ZWISLER | DIRECTOR/CHAIR (END 11/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| FRANCOIS FERRE PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GAIL K NAUGHTON PHD | DIRECTOR/CHAIR (START 11/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| GENEVIEVE T JACOBS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| HUNT PETTIT | DIRECTOR (END 05/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| J MARK WAXMAN JD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| KRISTINE CHARTON JD | DIRECTOR (END 11/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| LARRY S SPITCAUFSKY | DIRECTOR (END 05/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| LYNDA STUART MD PHD | DIRECTOR (END 11/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| MARK V BOWLES | DIRECTOR (END 02/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| MICHAEL D COIT | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| MITSUO SATOH PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| PAMELA K WASSERMAN MPH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| PAUL THIEL | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD S BODMAN | DIRECTOR (END 08/21) | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT C DYNES PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT W MAHLEY MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SANDOR W SHAPERY JD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| THOMAS L TULLIE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
2020 · 36 people listed · 9 paid, $4.2M · 478 employees · 84 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Mitchell Kronenberg | President & CSO | 40 | $580,450 | $0 | $77,787 | $658,237 | 3 |
| Alessandro Sette | Division Head/Center Head/Prof | 40 | $524,511 | $0 | $98,265 | $622,776 | 1 |
| Stephen Wilson | EVP, COO & CTO | 40 | $442,704 | $0 | $100,765 | $543,469 | 1 |
| Erica Saphire | Professor | 40 | $387,759 | $0 | $67,026 | $454,785 | 1 |
| Michael Croft | Division Head/Professor | 40 | $333,908 | $0 | $72,831 | $406,739 | 1 |
| Catherine Hedrick | Professor | 40 | $334,888 | $0 | $69,759 | $404,647 | 1 |
| Klaus Ley | Division Head/Professor | 40 | $316,999 | $0 | $59,055 | $376,054 | 1 |
| Stephen P Schoenberger | Professor | 40 | $277,591 | $0 | $78,300 | $355,891 | 1 |
| Michael Dollar | CFO | 40 | $283,029 | $0 | $48,165 | $331,194 | 1 |
| Anthony Carr | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Barton J Cohen | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David A Brenner MD | Director | 2 | $0 | $0 | $0 | $0 | 4 |
| David Dominguez | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David M Rickey | Director (Start 02/27/2020) | 2 | $0 | $0 | $0 | $0 | 1 |
| David R Webb PhD | Director | 2 | $0 | $0 | $0 | $0 | 3 |
| Eric V Zwisler | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Franois Ferr PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Gail K Naughton PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Genevive T Jacobs | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Hunt Pettit | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| J Mark Waxman JD | Director (Start 02/27/2020) | 2 | $0 | $0 | $0 | $0 | 1 |
| John E Major Chair | Director (End 05/29/2020) | 2 | $0 | $0 | $0 | $0 | 1 |
| Kristine Charton JD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Larry S Spitcaufsky | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Lynda Stuart MD PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Mark V Bowles | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Michael D Coit | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Mitsuo Satoh PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Pamela K Wasserman MPH | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Paul Thiel | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Richard S Bodman | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Robert C Dynes PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Robert W Mahley MD PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Sandor W Shapery JD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Thomas L Tullie | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Vanessa V Wertheim PhD MBA RN | Director (End 05/19/2020) | 2 | $0 | $0 | $0 | $0 | 3 |
2019 · 35 people listed · 10 paid, $3.9M · 479 employees · 65 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Mitchell Kronenberg | President & CSO | 40 | $541,764 | $0 | $85,071 | $626,835 | 3 |
| Alessandro Sette | Division Head/Center Head/Prof | 40 | $425,416 | $0 | $96,752 | $522,168 | 1 |
| Stephen Wilson | EVP, COO & CTO | 40 | $386,862 | $0 | $98,035 | $484,897 | 1 |
| Michael Croft | Director Scientific Affairs | 40 | $323,176 | $0 | $71,232 | $394,408 | 1 |
| Catherine Hedrick | Professor | 40 | $325,110 | $0 | $68,183 | $393,293 | 1 |
| Klaus Ley | Division Head/Professor | 40 | $316,529 | $0 | $58,977 | $375,506 | 1 |
| Stephen P Schoenberger | Professor | 40 | $288,333 | $0 | $82,469 | $370,802 | 1 |
| Hilde Cheroutre | Division Head/Professor | 40 | $294,002 | $0 | $55,624 | $349,626 | 3 |
| Jennifer K Keyes | CFO (End 06/18/2019) | 40 | $215,861 | $0 | $21,211 | $237,072 | 1 |
| Michael Dollar | CFO (Start 06/24/2019) | 40 | $146,986 | $0 | $13,682 | $160,668 | 1 |
| Richard S Bodman | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Mark V Bowles | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David A Brenner MD | Director | 2 | $0 | $0 | $0 | $0 | 4 |
| Anthony Carr | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Kristine Charton JD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Barton J Cohen | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Michael D Coit | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David Dominguez | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Robert C Dynes PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Franois Ferre PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Genevive T Jacobs | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Robert W Mahley MD PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| John E Major Chair | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Gail K Naughton PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Hunt Pettit | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Mitsuo Satoh PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Sandor W Shapery JD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Larry S Spitcaufsky | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Lynda Stuart MD PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Paul Thiel | Director (Start 08/2019) | 2 | $0 | $0 | $0 | $0 | 1 |
| Thomas L Tullie | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Pamela K Wasserman MPH | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David R Webb PhD | Director | 2 | $0 | $0 | $0 | $0 | 3 |
| Vanessa V Wertheim PhD MBA RN | Director | 2 | $0 | $0 | $0 | $0 | 3 |
| Eric V Zwisler | Director | 2 | $0 | $0 | $0 | $0 | 1 |
2017 · 35 people listed · 9 paid, $3.5M · 418 employees · 99 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Mitchell Kronenberg PhD | President & CSO | 40 | $523,837 | $0 | $59,515 | $583,352 | 3 |
| Alessandro Sette | Center Head/Division Head/Pro | 40 | $406,128 | $0 | $66,094 | $472,222 | 1 |
| Stephen Wilson | EVP, Chief Administrative Officer | 40 | $355,522 | $0 | $73,630 | $429,152 | 1 |
| Klaus Ley | Division Head/Professor | 40 | $344,683 | $0 | $50,161 | $394,844 | 1 |
| Amnon Altman | Director, Scientific Affairs | 40 | $321,960 | $0 | $63,339 | $385,299 | 1 |
| Stephen P Schoenberger | Professor | 40 | $308,279 | $0 | $69,630 | $377,909 | 1 |
| Catherine Hedrick | Professor | 40 | $308,280 | $0 | $57,605 | $365,885 | 1 |
| Hilde Cheroutre | Division Head/Professor | 40 | $278,809 | $0 | $50,180 | $328,989 | 3 |
| Jennifer K Keyes | CFO | 40 | $175,019 | $0 | $35,925 | $210,944 | 1 |
| Pamela W Blakely | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Richard S Bodman | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Mark V Bowles | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David A Brenner MD | Director | 2 | $0 | $0 | $0 | $0 | 4 |
| Anthony Carr | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Kristine Charton JD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Barton J Cohen | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Michael D Coit | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David Dominguez | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Robert C Dynes PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Francois Ferre PhD | Director (Start 02/10/17) | 2 | $0 | $0 | $0 | $0 | 1 |
| Sergio Jinich | Director (End 04/03/2017) | 2 | $0 | $0 | $0 | $0 | 1 |
| Richard K Kornfeld | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Robert W Mahley MD PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| John E Major | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Gail K Naughton PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Hiroshi Okazaki PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Hunt Pettit | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Larry S Spitcaufsky | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Thomas L Tullie | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David L Steffy | Director (Start 08/11/17) | 2 | $0 | $0 | $0 | $0 | 1 |
| Fred Wasserman MBA DrPH | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David R Webb PhD | Director | 2 | $0 | $0 | $0 | $0 | 3 |
| Herbert A Wertheim OK DSC | Director (End 05/19/17) | 2 | $0 | $0 | $0 | $0 | 1 |
| Vanessa V Wertheim PhD MBA RN | Director (Start 05/19/17) | 2 | $0 | $0 | $0 | $0 | 3 |
| Eric V Zwisler | Director | 2 | $0 | $0 | $0 | $0 | 1 |
2016 · 36 people listed · 9 paid, $3.4M · 421 employees · 93 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Mitchell Kronenberg PhD | President/CSO | 40 | $472,206 | $0 | $57,544 | $529,750 | 3 |
| Alessandro Sette | Center Head/Division Head/Prof | 40 | $368,968 | $0 | $66,631 | $435,599 | 1 |
| Amnon Altman | Dir, Scientific Affairs | 40 | $332,256 | $0 | $61,482 | $393,738 | 1 |
| Klaus Ley | Division Head/Professor | 40 | $333,459 | $0 | $49,945 | $383,404 | 1 |
| Stephen Wilson | EVP Chief Administrative Officer | 40 | $320,310 | $0 | $58,594 | $378,904 | 1 |
| Stephen P Schoenberger | Professor | 40 | $309,553 | $0 | $66,597 | $376,150 | 1 |
| Joel Linden | Professor | 40 | $282,900 | $0 | $60,095 | $342,995 | 1 |
| Hilde Cheroutre | Division Head/Professor | 40 | $269,445 | $0 | $49,166 | $318,611 | 3 |
| Jennifer K Keyes | CFO | 40 | $162,407 | $0 | $33,432 | $195,839 | 1 |
| Pamela W Blakely | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Richard S Bodman | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Mark V Bowles | Director (start 2/12/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| David A Brenner MD | Director (start 5/13/16) | 2 | $0 | $0 | $0 | $0 | 4 |
| Anthony Carr | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Kristine Charton JD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Barton J Cohen | Director (start 02/12/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| Michael D Coit | Director (start 11/18/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| David Dominguez | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Robert C Dynes PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Leroy Hood MD PhD | Director (end 7/29/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| Sergio Jinich | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Richard K Kornfeld | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Robert W Mahley MD PhD | Director (start 8/12/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| John E Major | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Toshifumi Mikayama PhD | Director (end 2/13/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| Gail K Naughton PhD | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Hiroshi Okazaki PhD | Director (start 2/13/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| David A Perkins | Director (end 4/4/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| Hunt Pettit | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Rhonda F Rhyne | Director (end 11/12/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| Larry S Spitcaufsky | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Thomas L Tullie | Director (start 8/12/16) | 2 | $0 | $0 | $0 | $0 | 1 |
| Fred Wasserman DrPH | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| David R Webb PhD | Director | 2 | $0 | $0 | $0 | $0 | 3 |
| Herbert A Wertheim OK DSC | Director | 2 | $0 | $0 | $0 | $0 | 1 |
| Eric V Zwisler | Director | 2 | $0 | $0 | $0 | $0 | 1 |
2015 · 32 people listed · 9 paid, $3.2M · 399 employees · 129 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| MITCHELL KRONENBERG PHD | PRESIDENT/CSO | 40 | $458,941 | $0 | $56,940 | $515,881 | 3 |
| ALESSANDRO SETTE | CENTER HEAD/DIVISION HEAD/PROFESSOR | 40 | $335,396 | $0 | $66,696 | $402,092 | 1 |
| AMNON ALTMAN | DIR, SCIENTIFIC AFFAIRS | 40 | $333,854 | $0 | $61,407 | $395,261 | 1 |
| KLAUS LEY | DIVISION HEAD/PROFESSOR | 40 | $324,973 | $0 | $49,028 | $374,001 | 1 |
| STEPHEN P SCHOENBERGER | PROFESSOR | 40 | $288,192 | $0 | $66,696 | $354,888 | 1 |
| STEPHEN WILSON | EVP, CHIEF ADMINISTRATIVE OFFICER | 40 | $294,138 | $0 | $55,922 | $350,060 | 1 |
| JOEL LINDEN | PROFESSOR | 40 | $286,834 | $0 | $47,306 | $334,140 | 1 |
| HILDE CHEROUTRE | DIVISION HEAD/PROFESSOR | 40 | $260,285 | $0 | $48,040 | $308,325 | 3 |
| JENNIFER K KEYES | CFO | 40 | $149,448 | $0 | $18,940 | $168,388 | 1 |
| PAMELA W BLAKELY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ANTHONY CARR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOMINGUEZ | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT C DYNES PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| LEROY HOOD MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SERGIO JINICH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD K KORNFELD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| JOHN E MAJOR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TOSHIFUMI MIKAYAMA PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GAIL K NAUGHTON PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TINA S NOVA PHD | DIRECTOR (THROUGH 06/02/2015) | 2 | $0 | $0 | $0 | $0 | 9 |
| DAVID A PERKINS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GENE W RAY PHD | DIRECTOR (THROUGH 07/01/2015) | 2 | $0 | $0 | $0 | $0 | 1 |
| RHONDA F RHYNE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| FRED WASSERMAN DRPH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID R WEBB PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| HERBERT A WERTHEIM OK DSC | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TIMOTHY J WOLLAEGER | DIRECTOR (THROUGH 11/15/2015) | 2 | $0 | $0 | $0 | $0 | 1 |
| ERIC V ZWISLER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| KRISTINE CHARTON JD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| LARRY S SPITCAUFSKY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| HUNT PETTIT | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD S BODMAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
2014 · 31 people listed · 11 paid, $3.6M · 413 employees · 48 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| MITCHELL KRONENBERG PHD | PRESIDENT/CSO | 40 | $437,074 | $0 | $55,362 | $492,436 | 3 |
| ALESSANDRO SETTE | CENTER HEAD/DIVISION HEAD/PROFESSOR | 40 | $324,302 | $0 | $64,932 | $389,234 | 1 |
| AMNON ALTMAN | DIR, SCIENTIFIC AFFAIRS | 40 | $322,782 | $0 | $60,483 | $383,265 | 1 |
| ANJANA RAO | DIVISION HEAD/PROFESSOR | 40 | $319,129 | $0 | $48,192 | $367,321 | 1 |
| KLAUS LEY | DIVISION HEAD/PROFESSOR | 40 | $306,497 | $0 | $50,711 | $357,208 | 1 |
| JOEL LINDEN | PROFESSOR | 40 | $286,465 | $0 | $48,192 | $334,657 | 1 |
| CHARLES CARPOWICH | EVP/COO/CFO THROUGH 11/21/2013 | 0 | $323,783 | $0 | $0 | $323,783 | 1 |
| STEPHEN WILSON | EVP, CHIEF ADMINISTRATIVE OFFICER | 40 | $253,547 | $0 | $61,752 | $315,299 | 1 |
| HILDE CHEROUTRE | DIVISION HEAD/PROFESSOR | 40 | $260,289 | $0 | $47,973 | $308,262 | 3 |
| TAI NGUYEN | CFO THROUGH 08/18/2014 | 40 | $188,174 | $0 | $28,099 | $216,273 | 1 |
| JENNIFER K KEYES | CFO | 40 | $67,878 | $0 | $4,437 | $72,315 | 1 |
| PAMELA W BLAKELY | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ANTHONY CARR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOMINGUEZ | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT C DYNES PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| LEROY HOOD MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SERGIO JINICH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD K KORNFELD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| JOHN E MAJOR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TOSHIFUMI MIKAYAMA PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GAIL K NAUGHTON PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TINA S NOVA PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 9 |
| DAVID A PERKINS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GENE W RAY PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RHONDA F RHYNE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| FRED WASSERMAN DRPH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID R WEBB PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| HERBERT A WERTHEIM OK DSC | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TIMOTHY J WOLLAEGER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ERIC V ZWISLER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| CHARLES J CASHION | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
2013 · 28 people listed · 9 paid, $3.2M · 390 employees · 48 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| MITCHELL KRONENBERG PHD | PRESIDENT/CSO | 40 | $428,510 | $0 | $50,040 | $478,550 | 3 |
| CHARLES CARPOWICH | EVP/COO/CFO | 40 | $332,314 | $0 | $58,274 | $390,588 | 1 |
| ALESSANDRO SETTE | CENTER HEAD/DIVISION HEAD/PROFESSOR | 40 | $313,701 | $0 | $57,982 | $371,683 | 1 |
| AMNON ALTMAN | DIR, SCIENTIFIC AFFAIRS | 40 | $311,377 | $0 | $52,780 | $364,157 | 1 |
| ANJANA RAO | DIVISION HEAD/PROFESSOR | 40 | $311,441 | $0 | $46,623 | $358,064 | 1 |
| KLAUS LEY | DIVISION HEAD/PROFESSOR | 40 | $277,006 | $0 | $52,780 | $329,786 | 1 |
| JOEL LINDEN | PROFESSOR | 40 | $279,460 | $0 | $46,623 | $326,083 | 1 |
| HILDE CHEROUTRE | DIVISION HEAD/PROFESSOR | 40 | $253,914 | $0 | $46,209 | $300,123 | 3 |
| STEPHEN WILSON | EVP CHIEF TECH. OFFICER | 40 | $238,734 | $0 | $48,626 | $287,360 | 1 |
| ANTHONY CARR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| CHARLES J CASHION | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOMINGUEZ | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT C DYNES PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| LEROY HOOD MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SERGIO JINICH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD K KORNFELD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| JOHN E MAJOR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TOSHIFUMI MIKAYAMA PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GAIL K NAUGHTON PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TINA S NOVA PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 9 |
| DAVID A PERKINS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GENE W RAY PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RHONDA F RHYNE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| FRED WASSERMAN DRPH | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID R WEBB PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| HERBERT A WERTHEIM OK DSC | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TIMOTHY J WOLLAEGER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| SAMUEL STROBER MD | FORMER DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
2012 · 25 people listed · 11 paid, $3.3M · 382 employees · 48 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| MITCHELL KRONENBERG PHD | PRESIDENT/CSO | 40 | $413,510 | $0 | $49,518 | $463,028 | 3 |
| CHARLES CARPOWICH | EVP/COO/CFO | 40 | $310,727 | $0 | $57,528 | $368,255 | 1 |
| ALESSANDRO SETTE | CENTER HEAD/PROFESSOR | 40 | $305,974 | $0 | $57,528 | $363,502 | 1 |
| AMNON ALTMAN | DIR, SCIENTIFIC AFFAIRS | 40 | $302,363 | $0 | $52,293 | $354,656 | 1 |
| ANJANA RAO | DIVISION HEAD/PROFESSOR | 40 | $303,593 | $0 | $46,076 | $349,669 | 1 |
| KLAUS LEY | DIVISION HEAD/PROFESSOR | 40 | $287,914 | $0 | $52,274 | $340,188 | 1 |
| JOEL LINDEN | PROFESSOR | 40 | $279,108 | $0 | $46,076 | $325,184 | 1 |
| HILDE CHEROUTRE | DIVISION HEAD/PROFESSOR | 40 | $248,224 | $0 | $45,471 | $293,695 | 3 |
| STEPHEN WILSON | EVP CHIEF TECH. OFFICER | 40 | $223,874 | $0 | $55,528 | $279,402 | 1 |
| MARYANN STEWART | FORMER VP CHIEF DEV. OFFICER | 0 | $130,744 | $0 | $0 | $130,744 | 1 |
| SAMUEL STROBER MD | DIRECTOR | 2 | $1,500 | $0 | $0 | $1,500 | 1 |
| CHARLES J CASHION | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOMINGUEZ | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT C DYNES PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| LEROY HOOD MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD K KORNFELD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| JOHN E MAJOR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TOSHIFUMI MIKAYAMA PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| GAIL K NAUGHTON PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID A PERKINS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RHONDA F RHYNE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID R WEBB PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
| MARK FISCHER | FORMER DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| MICHAEL MARTIN | FORMER DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM ROHN | FORMER DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
2011 · 22 people listed · 11 paid, $3.2M · 386 employees · 53 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| MITCHELL KRONENBERG PHD | PRESIDENT/CSO | 40 | $397,469 | $0 | $47,911 | $445,380 | 3 |
| CHARLES CARPOWICH | EVP/COO/CFO | 40 | $308,605 | $0 | $55,276 | $363,881 | 1 |
| ALESSANDRO SETTE | CENTER HEAD/PROFESSOR | 40 | $300,166 | $0 | $47,839 | $348,005 | 1 |
| AMNON ALTMAN | DIR, SCIENTIFIC AFFAIRS | 40 | $295,016 | $0 | $50,449 | $345,465 | 1 |
| KLAUS LEY | DIVISION HEAD/PROFESSOR | 40 | $289,057 | $0 | $50,430 | $339,487 | 1 |
| JOEL LINDEN | PROFESSOR | 40 | $270,283 | $0 | $44,729 | $315,012 | 1 |
| ANJANA RAO | DIVISION HEAD/PROFESSOR | 40 | $276,841 | $0 | $28,604 | $305,445 | 1 |
| STEPHEN SCHOENBERGER | PROFESSOR | 40 | $244,331 | $0 | $49,454 | $293,785 | 1 |
| STEPHEN WILSON | VP CHIEF TECH. OFFICER | 40 | $198,422 | $0 | $50,267 | $248,689 | 1 |
| MARYANN STEWART | VP CHIEF DEV. OFFICER | 40 | $162,676 | $0 | $29,147 | $191,823 | 1 |
| SAMUEL STROBER MD | DIRECTOR | 2 | $6,000 | $0 | $0 | $6,000 | 1 |
| MARK FISCHER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD KORNFELD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| MICHAEL MARTIN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TOSHIFUMI MIKAYAMA PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOMINGUEZ | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT DYNES PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| LEROY HOOD MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| JOHN MAJOR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RHONDA RHYNE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM ROHN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID WEBB PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 3 |
2010 · 26 people listed · 12 paid, $3.1M · 393 employees · 9 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| MITCHELL KRONENBERG PHD | PRESIDENT/CSO | 40 | $389,584 | $0 | $47,408 | $436,992 | 3 |
| CHARLES CARPOWICH | EVP/COO | 40 | $299,208 | $0 | $54,394 | $353,602 | 1 |
| ALESSANDRO SETTE | CENTER HEAD/MEMBER | 40 | $294,164 | $0 | $47,339 | $341,503 | 1 |
| AMNON ALTMAN | DIRECTOR, SCIENTIFIC AFFAIRS | 40 | $290,248 | $0 | $49,803 | $340,051 | 1 |
| KLAUS LEY | DIVISION HEAD/MEMBER | 40 | $283,801 | $0 | $49,784 | $333,585 | 1 |
| STEPHEN SCHOENBERGER | MEMBER | 40 | $246,998 | $0 | $42,548 | $289,546 | 1 |
| JOEL LINDEN | DIVISION HEAD/MEMBER | 40 | $265,102 | $0 | $20,755 | $285,857 | 1 |
| STEPHEN WILSON | VP CHIEF TECH. OFFICER | 40 | $195,154 | $0 | $48,158 | $243,312 | 1 |
| MARYANN STEWART | VP CHIEF DEV. OFFICER | 40 | $203,328 | $0 | $39,486 | $242,814 | 1 |
| CARL WARE | DIVISION HEAD/MEMBER | 40 | $185,944 | $0 | $31,415 | $217,359 | 1 |
| SAMUEL STROBER MD | DIRECTOR | 2 | $6,000 | $0 | $0 | $6,000 | 1 |
| SUSAN SWAIN PHD | DIRECTOR | 2 | $5,500 | $0 | $0 | $5,500 | 1 |
| JOHN MAJOR | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| MARK FISCHER | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RHONDA RHYNE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| WILLIAM ROHN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| ROBERT DYNES PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| LEROY HOOD MD PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| HAROLD BUCHANAN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| KATINA TSAKOPOULOS | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| RICHARD KORNFELD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| MICHAEL MARTIN | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| TOSHIFUMI MIKAYAMA PHD | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| DAVID DOMINGUEZ | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
| KIMISHIGE ISHIZAKA MD PHD | DIRECTOR/EMERITUS | 2 | $0 | $0 | $0 | $0 | 1 |
| STEVEN ODRE | DIRECTOR | 2 | $0 | $0 | $0 | $0 | 1 |
Highest-paid independent contractors
2024 · 4 contractors · $638K
| Name | Location | Service | Paid |
|---|---|---|---|
| FOLEY LARDNER LLP | MILWAUKEE, WI | LEGAL AND PROFESSIONAL SERVICES | $207,828 |
| UNIVERSAL BUILDING MAINTENANCE LLC | PASADENA, CA | COMMERCIAL CLEANING SERVICES | $172,694 |
| UNIVERSAL PROTECTION SERVICES LP | PASADENA, CA | SECURITY SERVICES | $155,283 |
| CHALKER FLORES LLP | DALLAS, TX | LEGAL AND PROFESSIONAL SERVICES | $102,196 |
2023 · 4 contractors · $678K
| Name | Location | Service | Paid |
|---|---|---|---|
| UNIVERSAL BUILDING MAINTENANCE LLC | PASADENA, CA | COMMERCIAL CLEANING SERVICES | $198,649 |
| UNIVERSAL PROTECTION SERVICES LP | PASADENA, CA | SECURITY SERVICES | $168,815 |
| MOSS-ADAMS LLP | SEATTLE, WA | ACCOUNTING SERVICES | $162,310 |
| FOLEY LARDNER LLP | MILWAUKEE, WI | LEGAL SERVICES | $148,113 |
2022 · 5 contractors · $927K
| Name | Location | Service | Paid |
|---|---|---|---|
| CPA CALINI | SAN DIEGO, CA | ACCOUNTING SERVICES | $349,400 |
| ALLIED UNIVERSAL JANITORIAL SERVICES | PASADENA, CA | COMMERCIAL CLEANING SERVICES | $182,662 |
| ALLIED UNIVERSAL SECURITY SERVICES | PASADENA, CA | SECURITY SERVICES | $158,662 |
| MOSS-ADAMS LLP | PASADENA, CA | ACCOUNTING SERVICES | $120,285 |
| LARRABEE ALBI COKER LLP | SAN DIEGO, CA | LEGAL SERVICES | $116,000 |
2021 · 5 contractors · $640K
| Name | Location | Service | Paid |
|---|---|---|---|
| NATHANIEL S WANG | SAN DIEGO, CA | CONSULTING SERVICES | $140,250 |
| DUANE MORRIS LLP | PHILADELPHIA, PA | LEGAL SERVICES | $131,497 |
| MOSS-ADAMS | PASADENA, CA | ACCOUNTING SERVICES | $124,905 |
| FOLEY & LARDNER | MILWAUKEE, WI | LEGAL SERVICES | $121,824 |
| UNIVERSAL BUILDING MAINTENANCE | PASADENA, CA | COMMERCIAL CLEANING SERVICES | $121,302 |
2020 · 5 contractors · $1.9M
| Name | Location | Service | Paid |
|---|---|---|---|
| A&A Labs LLC | San Diego, CA | Lab supplies | $827,576 |
| Pestotnik LLP | San Diego, CA | Legal services | $412,210 |
| Zalgen Labs LLC | Germantown, MD | AB services | $328,339 |
| 1903 Solutions LLC | Newport Beach, CA | Computer hardware and security | $174,164 |
| ML Weekes & Company PC | Guilford, CT | Consulting | $163,452 |
2019 · 5 contractors · $921K
| Name | Location | Service | Paid |
|---|---|---|---|
| Finley & Cook | Shawnee, OK | ERP software | $303,686 |
| A&A Labs LLC | San Diego, CA | Lab Supplies | $273,099 |
| Pestotnik LLP | San Diego, CA | Patient Related (Legal and Prof. Sv) | $121,902 |
| Moss-Adams LLP | Pasadena, CA | Auditor (Audit Organization Financial) | $112,300 |
| 1903 Solutions LLC | Newport Beach, CA | Computer Hardware/Fortigate and security | $109,957 |
2017 · 5 contractors · $945K
| Name | Location | Service | Paid |
|---|---|---|---|
| Thien Douglas Y | Menlo Park, CA | Consultant to provide services and asses | $310,000 |
| Pillsbury Winthrop Shaw Pittman LLP | Los Angeles, CA | Patent Related (Legal and Professional | $220,191 |
| Ho Patrick | Carlsbad, CA | Consulting service | $182,291 |
| 1903 Solutions LLC | Newport Beach, CA | IT Web Support for Forti Analyzer | $126,005 |
| Moss-Adams LLP | Pasadena CA, CA | Auditor (audit the Organization's financ | $106,855 |
2015 · 1 contractor · $145K
| Name | Location | Service | Paid |
|---|---|---|---|
| PILLSBURY WINTHROP SHAW PITTMAN LLP | LOS ANGELES, CA | PATENT RELATED | $144,988 |
2014 · 2 contractors · $281K
| Name | Location | Service | Paid |
|---|---|---|---|
| SOL PACIFIC LLC | SAN DIEGO, CA | JANITORIAL SERVICES | $141,815 |
| PILLSBURY WINTHROP SHAW PITTMAN LLP | LOS ANGELES, CA | PATENT RELATED | $139,565 |
2013 · 3 contractors · $408K
| Name | Location | Service | Paid |
|---|---|---|---|
| PILLSBURY WINTHROP SHAW PITTMAN LLP | PATENT SERVICES | $167,177 | |
| SOL PACIFIC LLC | JANITORIAL SERVICES | $137,421 | |
| WARD BONNIE | EXTERNAL RELATIONS/PR SERVICES | $103,894 |
2012 · 2 contractors · $281K
| Name | Location | Service | Paid |
|---|---|---|---|
| SOL PACIFIC LLC | SAN DIEGO, CA | JANITORIAL SERVICES | $153,745 |
| PILLSBURY WINTHROP SHAW PITTMAN | LOS ANGELES, CA | LEGAL SERVICES-PATENT | $127,584 |
2011 · 3 contractors · $631K
| Name | Location | Service | Paid |
|---|---|---|---|
| PILLSBURY WINTHROP SHAW PITTMAN LLP | SAN FRANCISCO, CA | PATENT SERVICES | $391,744 |
| SOL PACIFIC LLC | SAN DIEGO, CA | JANITORIAL SERVICES | $135,253 |
| 2COR PARTNERS INC | RANCHO SANTA FE, CA | DEVELOPMENT CONSULTING SERVICES | $104,416 |
2010 · 2 contractors · $267K
| Name | Location | Service | Paid |
|---|---|---|---|
| SOL PACIFIC LLC | SAN DIEGO, CA | JANITORIAL SERVICES | $133,788 |
| PILLSBURY WINTHROP SHAW PITTMAN LLP | SAN FRANCISCO, CA | LEGAL | $133,276 |
Who the money went to
Grants this organization reported paying: Schedule I Part II of the Form 990, or the grants-paid list on the 990-PF. Open a year for every recipient. Recipients link to their own page when the grant names an EIN we have (990-PF grants list no EIN, so those link only on an exact, unique name and state). Grants to individuals are counted; their names are not shown.
2024 · 36 grants to organizations · $10.3M
Listed grants add up to $10,327,878; the return's “grants paid” expense line says $11,383,266. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2023 · 32 grants to organizations · $8.7M
Listed grants add up to $8,729,443; the return's “grants paid” expense line says $8,255,025. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2022 · 31 grants to organizations · $10.6M
Listed grants add up to $10,626,734; the return's “grants paid” expense line says $14,115,363. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2021 · 35 grants to organizations · $13.1M
Listed grants add up to $13,088,315; the return's “grants paid” expense line says $14,235,330. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2019 · 1 grant to organizations · $6K
Listed grants add up to $6,000; the return's “grants paid” expense line says $769,190. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2017 · 1 grant to organizations · $6K
2016 · 1 grant to organizations · $10K
Negative amounts are returned or refunded grants; they are listed last and left out of the totals of grants paid.
Who gave
Contributor names are not public for this form type.
Public charities filing Form 990 or 990-EZ report large donors on Schedule B, but the IRS withholds their names and addresses from public copies. Private foundations (990-PF) are different: their contributors are public.
Finances
Newest first. Each filing: its name on one row, its figures on the row beneath. Greyed filings are superseded by a later return for the same period and are left out everywhere else on this page.
| Revenue | Expenses | Assets | Net assets | Contributions | Program revenue | Officer pay | Employees | Volunteers |
|---|---|---|---|---|---|---|---|---|
| 2024 · Form 990 | ||||||||
| $84,154,783 | $86,007,343 | $62,503,266 | $27,513,582 | $57,829,181 | $21,278,774 | $2,827,411 | 462 | 106 |
| 2023 · Form 990 | ||||||||
| $75,554,472 | $83,691,328 | $65,342,422 | $29,546,895 | $50,892,160 | $20,407,924 | $2,607,081 | 464 | 107 |
| 2022 · Form 990 | ||||||||
| $92,274,481 | $92,177,095 | $80,295,864 | $36,483,885 | $65,156,062 | $23,862,556 | $1,844,389 | 515 | 151 |
| 2021 · Form 990 | ||||||||
| $102,015,351 | $85,939,425 | $70,149,069 | $39,093,304 | $73,055,647 | $23,482,463 | $2,361,001 | 501 | 111 |
| 2020 · Form 990 | ||||||||
| $80,623,646 | $81,170,041 | $60,537,089 | $22,942,694 | $67,178,581 | $11,469,412 | $1,939,639 | 478 | 84 |
| 2019 · Form 990 | ||||||||
| $68,642,455 | $70,159,237 | $50,722,461 | $23,489,089 | $58,096,830 | $7,349,335 | $1,666,808 | 479 | 65 |
| 2017 · Form 990 | ||||||||
| $58,030,116 | $58,276,909 | $37,144,519 | $27,376,504 | $49,333,077 | $5,797,546 | $1,608,747 | 418 | 99 |
| 2016 · Form 990 | ||||||||
| $59,404,260 | $57,981,481 | $38,148,822 | $27,623,297 | $51,251,936 | $6,329,766 | $1,498,231 | 421 | 93 |
| 2015 · Form 990 | ||||||||
| $61,557,685 | $52,815,911 | $36,797,526 | $26,318,918 | $55,660,152 | $5,213,453 | $1,429,590 | 399 | 129 |
| 2014 · Form 990 | ||||||||
| $49,515,524 | $51,646,368 | $27,661,104 | $17,577,144 | $44,790,248 | $4,058,346 | $1,263,315 | 413 | 48 |
| 2013 · Form 990 | ||||||||
| $52,399,088 | $52,043,703 | $31,683,652 | $19,707,988 | $46,742,132 | $4,663,486 | $1,520,653 | 390 | 48 |
| 2012 · Form 990 | ||||||||
| $49,232,647 | $48,077,169 | $29,571,824 | $19,352,603 | $43,599,639 | $3,110,250 | $1,466,841 | 382 | 48 |
| 2011 · Form 990 | ||||||||
| $48,434,968 | $46,314,239 | $27,262,976 | $18,197,125 | $43,377,978 | $3,608,126 | $1,601,236 | 386 | 53 |
| 2010 · Form 990 | ||||||||
| $43,632,368 | $45,816,501 | $30,922,104 | $16,076,396 | $38,763,253 | $4,264,931 | $1,627,521 | 393 | 9 |
Connected to
Organizations that list some of the same people on their returns (officers, directors, key employees on this organization’s latest return), and related organizations it lists on Schedule R.
- LA JOLLA IMMUNOLOGY CONFERENCE La Jolla, CA · 4 people in common (David R Webb, Hilde Cheroutre, Linda Sherman) · related organization (Schedule R)
- MIDWINTER CONFERENCE OF IMMUNOLOGISTS Sacramento, CA · 3 people in common (David R Webb, Hilde Cheroutre, Mitchell Kronenberg)
Funders of this organization
96 grantors reported grants to this organization, $94,970,930 in all, tax years 2009 to 2025; the 25 largest shown (all 96). Exact: the grantor wrote this organization's EIN. Fuzzy: the grantor wrote only a name (foundations' 990-PF has no EIN field), matched to the same or a near-identical name in the same state; the name as filed is shown. From the latest return for each grantor and year, so amended returns aren't counted twice. CSV
| Grantor | Total given | Grants | Latest year's amount | Latest year | Years given | Type | Match | Grants |
|---|---|---|---|---|---|---|---|---|
| SCRIPPS RESEARCH INSTITUTE | $14,427,028 | 5 | $3,716,736 | 2024 | 2020-2024 | Public charity | Exact | show |
| SERGEY BRIN FAMILY FOUNDATION | $13,548,720 | 4 | $1,359,560 | 2023 | 2020-2023 | Private foundation | Fuzzy filed as “LA JOLLA INSTITUTE FOR IMMUNOLOGY” | show |
| GATES FOUNDATION | $7,626,567 | 6 | $489,733 | 2024 | 2019-2022, 2024 | Private foundation | Fuzzy filed as “LA JOLLA INSTITUTE FOR IMMUNOLOGY” | show |
| EMORY UNIVERSITY | $4,552,477 | 15 | $182,400 | 2024 | 2010-2024 | Public charity | Exact | show |
| AMERICAN HEART ASSOCIATION INC | $4,070,912 | 10 | $300,000 | 2021 | 2010-2013, 2015-2019, 2021 | Public charity | Exact | show |
| CONRAD PREBYS FOUNDATION | $3,813,870 | 8 | $900,000 | 2024 | 2021-2024 | Private foundation | Fuzzy filed as “LA JOLLA INSTITUTE FOR IMMUNOLOGY” | show |
| FIDELITY INVESTMENTS CHARITABLE GIFT FUND | $3,619,314 | 9 | $685,350 | 2024 | 2016-2024 | DAF sponsor | Exact | show |
| WASHINGTON UNIVERSITY | $3,501,594 | 7 | $1,657,991 | 2024 | 2018-2024 | DAF sponsor | Exact | show |
| GHR FOUNDATION | $3,133,904 | 6 | $10,000 | 2023 | 2020-2023 | Private foundation | Fuzzy filed as “La Jolla Institute for Immunology”, “LA JOLLA INSTITUTE FOR IMMUNOLOGY” | show |
| INTERNATIONAL AIDS VACCINE INITIATIVE INC | $2,911,631 | 11 | $400,557 | 2025 | 2011-2015, 2020-2025 | Public charity | Exact | show |
| TRUSTEES OF COLUMBIA UNIVERSITY | $2,660,121 | 9 | $135,381 | 2024 | 2016-2024 | DAF sponsor | Exact | show |
| DONOR ADVISED CHARITABLE GIVING | $2,257,442 | 6 | $83,600 | 2024 | 2019-2024 | DAF sponsor | Exact | show |
| CUREBOUND INC | $1,985,719 | 4 | $385,027 | 2025 | 2022-2025 | Public charity | Exact | show |
| BLOOD CANCER UNITED INC | $1,825,000 | 16 | $60,000 | 2018 | 2010-2018 | Public charity | Exact | show |
| BRIGER FOUNDATION FOR ONCOLOGY RESEARCH INC | $1,687,786 | 1 | $1,687,786 | 2024 | 2024 | Private foundation | Fuzzy filed as “LA JOLLA INSTITUTE FOR IMMUNOLOGY” | show |
| BREAKTHROUGH T1D | $1,587,646 | 4 | $5,196 | 2013 | 2009-2010, 2012-2013 | Public charity | Exact | show |
| CANCER RESEARCH INSTITUTE INC | $1,345,990 | 8 | $33,100 | 2024 | 2010, 2014-2015, 2017, 2019, 2022-2024 | Public charity | Exact | show |
| W M KECK FOUNDATION | $1,300,000 | 1 | $1,300,000 | 2024 | 2024 | Private foundation | Fuzzy filed as “LA JOLLA INSTITUTE FOR IMMUNOLOGY” | show |
| JEWISH COMMUNITY FOUNDATION OF SAN DIEGO | $1,207,541 | 10 | $43,618 | 2024 | 2013-2015, 2018-2024 | DAF sponsor | Exact | show |
| SILICON VALLEY COMMUNITY FOUNDATION | $1,162,453 | 2 | $483,411 | 2022 | 2019, 2022 | DAF sponsor | Exact | show |
| DANA-FARBER CANCER INSTITUTE | $1,097,273 | 4 | $481,503 | 2012 | 2009-2012 | Public charity | Exact | show |
| THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | $1,079,802 | 29 | $34,491 | 2023 | 2019-2023 | Public charity | Exact | show |
| MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH | $1,041,978 | 3 | $142,215 | 2019 | 2016-2017, 2019 | Public charity | Exact | show |
| RANCHO SANTA FE FOUNDATION | $951,650 | 12 | $30,000 | 2025 | 2011-2013, 2016-2017, 2019-2025 | DAF sponsor | Exact | show |
| CROHNS & COLITIS FOUNDATION INC | $800,114 | 8 | $87,375 | 2021 | 2010, 2013-2015, 2018-2021 | Public charity | Exact | show |
Nearby + Similar BETA
Organizations like this one: what they do and who they are linked to
Same category: NTEE code and revenue
Ranked without any AI: same NTEE code first, then the same NTEE group; then revenue within 2x, 5x or 10x; then the same state; then similar name and mission text. NTEE: the IRS’s code when it lists one, otherwise FURP’s inferred code. Same state only · More (100)
| Organization | State | NTEE | Latest revenue | Latest expenses | Top-paid title | Top pay | Why similar |
|---|---|---|---|---|---|---|---|
| California Institute for BioMedical | CA | H99 | $98,797,059 | $40,377,736 | CEO/President & Chair | $721,397 | Same NTEE code H99, revenue within 2x, same state |
| ARC RESEARCH INSTITUTE | CA | H99 | $122,280,682 | $82,781,856 | CHIEF OPERATING OFFICER | $1,216,916 | Same NTEE code H99, revenue within 2x, same state |
| CHAN ZUCKERBERG BIOHUB INC | CA | H99 | $99,552,025 | $142,410,025 | DIRECTOR, PRESIDENT CZB SF (KEY EMP) | $965,995 | Same NTEE code H99, revenue within 2x, same state |
| CRITICAL PATH INSTITUTE | AZ | H99 | $46,783,745 | $40,232,360 | CEO | $519,080 | Same NTEE code H99, revenue within 2x |
| ARKANSAS CHILDRENS HOSPITAL RESEARCH INSTITUTE | AR | H99 | $71,774,036 | $62,900,517 | PRESIDENT/CEO-AR CHILDREN'S | $2,712,312 | Same NTEE code H99, revenue within 2x |
| TRILOGY INC | IL | H99 | $66,120,949 | $61,664,664 | CEO | $277,491 | Same NTEE code H99, revenue within 2x |
| THE RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE | H99 | $144,438,827 | $145,198,137 | DIRECTOR HR | $142,796 | Same NTEE code H99, revenue within 2x | |
| INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH | H99 | $77,723,739 | $73,163,020 | FINANCE DIRECTOR | $0 | Same NTEE code H99, revenue within 2x | |
| CITRUS RESEARCH AND DEVELOPMENT FOUNDATION INC | FL | H99 | $105,546,288 | $105,616,502 | RET CHIEF OP | $177,763 | Same NTEE code H99, revenue within 2x |
| ASSOCIATION OF PUBLIC HEALTH LABORATORIES INC | MD | H99 | $142,195,492 | $141,108,741 | CHIEF EXECUTIVE OFFICER | $1,058,150 | Same NTEE code H99, revenue within 2x |
| AMERICAN COLLEGE OF CHEST PHYSICIANS | IL | H99 | $48,404,043 | $39,901,044 | Secretary/Executive VP & CEO | $779,692 | Same NTEE code H99, revenue within 2x |
| SIR MORTIMER B DAVIS JEWISH GENERAL HOSPITAL | H99 | $47,967,963 | $48,839,095 | BOARD MEMBER/PRESIDENT & CEO | $236,316 | Same NTEE code H99, revenue within 2x | |
| FUTURE CRYONICS FOUNDATION | IA | H99 | $77,473,702 | $126,824 | President / Director | $0 | Same NTEE code H99, revenue within 2x |
| HENDERSON-WESSENDORFF FOUNDATION | TX | H99 | $44,288,793 | $23,193,068 | PRESIDENT | $578,087 | Same NTEE code H99, revenue within 2x |
| GEORGE S ECCLES AND DELORES DORE ECCLES FOUNDATION | UT | H99 | $52,369,983 | $52,841,394 | CEO/CHAIRMAN OF THE BOARD | $426,308 | Same NTEE code H99, revenue within 2x |
| ABBOTT FUND | IL | H99 | $55,570,056 | $23,942,569 | President and Director | $0 | Same NTEE code H99, revenue within 2x |
| CALIFORNIA INSTITUTE FOR IMMUNOLOGY AND IMMUNOTHERAPY | CA | H99 | $20,000,000 | $1,589,595 | BOARD CHAIR/DIRECTOR | $0 | Same NTEE code H99, revenue within 5x, same state, similar name |
| INSTITUT PASTEUR | H99 | $409,245,392 | $411,627,898 | THE PRESIDENT | $376,729 | Same NTEE code H99, revenue within 5x | |
| ARBOR RESEARCH COLLABORATIVE FOR HEALTH | MI | H99 | $20,353,298 | $19,007,337 | President | $740,767 | Same NTEE code H99, revenue within 5x |
| Rehabilitation Institute Research Corporation | IL | H99 | $17,473,369 | $18,672,795 | President, CEO | $1,208,934 | Same NTEE code H99, revenue within 5x |
| EVERY CURE INC | PA | H99 | $34,822,357 | $12,134,310 | CHIEF PHILANTHROPY OFFICER | $365,720 | Same NTEE code H99, revenue within 5x |
| NATIONAL ALLIANCE FOR RESEARCH ON SCHIZOPHRENIA AND DEPRESSION INC | NY | H99 | $27,686,049 | $16,481,525 | PRESIDENT & CEO | $648,461 | Same NTEE code H99, revenue within 5x |
| FRAUNHOFER USA INC | MI | H99 | $24,176,169 | $22,849,084 | SR. STRATEGIC ADVISOR | $395,743 | Same NTEE code H99, revenue within 5x |
| TRANSCELERATE BIOPHARMA INC | PA | H99 | $34,242,546 | $33,032,304 | CEO | $1,227,289 | Same NTEE code H99, revenue within 5x |
| MEDICAL DEVICE INNOVATION CONSORTIUM | VA | H99 | $28,171,331 | $28,147,444 | PRESIDENT & CEO | $914,419 | Same NTEE code H99, revenue within 5x |
Who funds organizations like this
Grantors that funded the 100 most similar organizations. Ranked by total given to them. Foundations (990-PF) and donor-advised fund sponsors only. Same matching as Funders above (by EIN, or by name for foundations).
The full list · all similar organizations
Where the money went
Every expense line on each return, biggest first: Form 990 Part IX (with its program, management and fundraising columns), 990-EZ Part I, or 990-PF Part I. Event marks lines the organization itself describes as events. “Events” in each summary adds those lines, conferences and meetings, and the direct costs of fundraising events. Unusual is not the same as improper. Many of these patterns have ordinary explanations. Check the filing.
2024 · Form 990 · $86,007,343 spent · pay $43,125,335 · grants $11,383,266 · events $121,601
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $31,202,912 | $25,985,921 | $4,503,188 | $713,803 | 36.3% | |
| Grants to US organizations and governments | $10,290,248 | $10,290,248 | - | - | 12.0% | |
| Other (as described) | LAB SUPPLIES & SERVICE | $9,316,406 | $9,308,872 | $7,534 | - | 10.8% |
| Occupancy | $6,745,806 | $6,166,334 | $550,816 | $28,656 | 7.8% | |
| Depreciation and depletion | $5,601,161 | $5,172,304 | $428,857 | - | 6.5% | |
| Other employee benefits | $3,420,862 | $2,837,875 | $491,597 | $91,390 | 4.0% | |
| Pension plan contributions | $3,026,645 | $2,510,841 | $434,945 | $80,859 | 3.5% | |
| Pay: officers, directors, trustees, key employees | $2,827,411 | $2,353,185 | $407,766 | $66,460 | 3.3% | |
| Other (as described) | MINOR EQUIPMENT AND REP | $2,643,104 | $2,630,530 | $11,952 | $622 | 3.1% |
| Payroll taxes | $2,263,978 | $1,878,148 | $325,346 | $60,484 | 2.6% | |
| Office expenses | $1,389,307 | $1,233,358 | $82,798 | $73,151 | 1.6% | |
| Fees: other services | $1,385,344 | $1,283,025 | $66,697 | $35,622 | 1.6% | |
| Travel | $1,270,944 | $1,045,601 | $161,251 | $64,092 | 1.5% | |
| Grants outside the US | $1,093,018 | $1,093,018 | - | - | 1.3% | |
| Information technology | $694,265 | $616,334 | $41,376 | $36,555 | 0.8% | |
| Fees: legal | $557,118 | $10,894 | $546,224 | - | 0.6% | |
| Advertising and promotion | $461,462 | $6,000 | $395,874 | $59,588 | 0.5% | |
| Insurance | $429,075 | $392,217 | $35,035 | $1,823 | 0.5% | |
| Pay: disqualified persons | $383,527 | $319,208 | $55,313 | $9,006 | 0.4% | |
| Fees: accounting | $350,596 | - | $350,596 | - | 0.4% | |
| Interest | $224,269 | - | $224,269 | - | 0.3% | |
| Other (as described) | OTHER EXPENSES | $184,278 | $74,311 | $85,074 | $24,893 | 0.2% |
| Conferences, conventions and meetings | $121,601 | $100,041 | $15,429 | $6,131 | 0.1% | |
| Fees: investment management | $57,416 | - | $57,416 | - | 0.1% | |
| Other (as described) | TAXES & DUES | $42,397 | $7,301 | $32,651 | $2,445 | 0.0% |
| Fees: professional fundraisers | $24,193 | - | - | $24,193 | 0.0% | |
| Total | $86,007,343 | 100% |
2023 · Form 990 · $83,691,328 spent · pay $42,616,230 · grants $8,255,025 · events $185,678
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $30,867,020 | $25,784,297 | $4,372,594 | $710,129 | 36.9% | |
| Other (as described) | LAB SUPPLIES & SERVICE | $9,148,413 | $9,148,413 | - | - | 10.9% |
| Occupancy | $7,085,642 | $6,503,448 | $553,404 | $28,790 | 8.5% | |
| Grants to US organizations and governments | $6,581,876 | $6,581,876 | - | - | 7.9% | |
| Depreciation and depletion | $5,801,730 | $5,357,459 | $444,271 | - | 6.9% | |
| Other employee benefits | $3,575,268 | $2,956,511 | $524,826 | $93,931 | 4.3% | |
| Pension plan contributions | $2,977,799 | $2,462,444 | $437,121 | $78,234 | 3.6% | |
| Other (as described) | MINOR EQUIPMENT AND REP | $2,840,313 | $2,822,924 | $16,529 | $860 | 3.4% |
| Pay: officers, directors, trustees, key employees | $2,607,081 | $2,174,378 | $371,399 | $61,304 | 3.1% | |
| Payroll taxes | $2,205,308 | $1,823,644 | $323,725 | $57,939 | 2.6% | |
| Fees: other services | $1,840,265 | $1,416,520 | $374,570 | $49,175 | 2.2% | |
| Grants outside the US | $1,673,149 | $1,673,149 | - | - | 2.0% | |
| Information technology | $1,304,152 | $1,003,794 | $247,312 | $53,046 | 1.6% | |
| Travel | $1,220,814 | $998,278 | $141,404 | $81,132 | 1.5% | |
| Office expenses | $893,403 | $687,644 | $169,420 | $36,339 | 1.1% | |
| Fees: legal | $530,326 | $13,079 | $517,247 | - | 0.6% | |
| Other (as described) | OTHER EXPENSES | $494,353 | $263,949 | $227,425 | $2,979 | 0.6% |
| Insurance | $418,020 | $383,663 | $32,658 | $1,699 | 0.5% | |
| Pay: disqualified persons | $383,754 | $320,056 | $54,672 | $9,026 | 0.5% | |
| Fees: accounting | $335,680 | - | $335,680 | - | 0.4% | |
| Advertising and promotion | $307,093 | $41,883 | $186,309 | $78,901 | 0.4% | |
| Interest | $262,166 | - | $262,166 | - | 0.3% | |
| Conferences, conventions and meetings | $156,028 | $48,705 | $102,889 | $4,434 | 0.2% | |
| Fees: professional fundraisers | $78,449 | - | - | $78,449 | 0.1% | |
| Fees: investment management | $55,939 | - | $55,939 | - | 0.1% | |
| All other expenses | $35,459 | $3,356 | $27,404 | $4,699 | 0.0% | |
| Other (as described) | UBI TAXES | $11,828 | - | $11,828 | - | 0.0% |
| Fundraising events Event | direct expenses; gross income $10,278 | $29,650 | reported apart | |||
| Total | $83,691,328 | 100% |
2022 · Form 990 · $92,177,095 spent · pay $42,281,594 · grants $14,115,363 · events $209,914
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $31,503,569 | $26,256,366 | $4,540,396 | $706,807 | 34.2% | |
| Grants to US organizations and governments | $13,021,532 | $13,021,532 | - | - | 14.1% | |
| Other (as described) | LAB SUPPLIES & SERVICE | $10,898,511 | $10,898,228 | $283 | - | 11.8% |
| Occupancy | $7,490,876 | $6,875,043 | $585,106 | $30,727 | 8.1% | |
| Depreciation and depletion | $5,206,153 | $4,931,273 | $274,880 | - | 5.6% | |
| Other employee benefits | $3,699,270 | $3,156,437 | $453,851 | $88,982 | 4.0% | |
| Other (as described) | MINOR EQUIPMENT AND REP | $2,842,049 | $2,825,966 | $14,920 | $1,163 | 3.1% |
| Pension plan contributions | $2,779,396 | $2,371,546 | $340,995 | $66,855 | 3.0% | |
| Fees: other services | $2,678,701 | $1,850,760 | $731,156 | $96,785 | 2.9% | |
| Payroll taxes | $2,088,069 | $1,781,665 | $256,178 | $50,226 | 2.3% | |
| Information technology | $1,990,886 | $1,605,097 | $358,506 | $27,283 | 2.2% | |
| Pay: officers, directors, trustees, key employees | $1,844,389 | $1,542,181 | $260,634 | $41,574 | 2.0% | |
| Travel | $1,287,988 | $1,028,853 | $158,614 | $100,521 | 1.4% | |
| Grants outside the US | $1,093,831 | $1,093,831 | - | - | 1.2% | |
| All other expenses | $619,191 | $362,573 | $209,218 | $47,400 | 0.7% | |
| Office expenses | $581,166 | $468,549 | $104,653 | $7,964 | 0.6% | |
| Fees: legal | $575,174 | $4,399 | $570,775 | - | 0.6% | |
| Pay: disqualified persons | $366,901 | $321,340 | $40,224 | $5,337 | 0.4% | |
| Insurance | $337,720 | $309,963 | $26,384 | $1,373 | 0.4% | |
| Fees: accounting | $316,217 | - | $316,217 | - | 0.3% | |
| Interest | $299,312 | - | $299,312 | - | 0.3% | |
| Advertising and promotion | $239,312 | $69,581 | $150,267 | $19,464 | 0.3% | |
| Conferences, conventions and meetings | $209,914 | $58,734 | $144,542 | $6,638 | 0.2% | |
| Other (as described) | UBI TAXES | $66,866 | - | $66,866 | - | 0.1% |
| Other (as described) | DUES | $54,782 | $1,184 | $47,074 | $6,524 | 0.1% |
| Fees: investment management | $48,444 | - | $48,444 | - | 0.1% | |
| Fees: professional fundraisers | $36,876 | - | - | $36,876 | 0.0% | |
| Total | $92,177,095 | 100% |
2021 · Form 990 · $85,939,425 spent · pay $39,665,941 · grants $14,235,330 · events $128,753
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $28,910,109 | $24,632,552 | $3,653,064 | $624,493 | 33.6% | |
| Grants to US organizations and governments | $13,323,730 | $13,323,730 | - | - | 15.5% | |
| Other (as described) | LAB SUPPLIES & SERVICE | $10,698,113 | $10,687,029 | $11,084 | - | 12.4% |
| Occupancy | $6,246,373 | $5,749,833 | $472,319 | $24,221 | 7.3% | |
| Depreciation and depletion | $4,662,232 | $4,312,877 | $349,355 | - | 5.4% | |
| Other employee benefits | $3,573,947 | $3,037,855 | $428,874 | $107,218 | 4.2% | |
| Pension plan contributions | $2,635,962 | $2,240,568 | $316,315 | $79,079 | 3.1% | |
| Other (as described) | MINOR EQUIPMENT AND REP | $2,580,884 | $2,538,321 | $42,028 | $535 | 3.0% |
| Pay: officers, directors, trustees, key employees | $2,361,001 | $2,006,856 | $306,921 | $47,224 | 2.7% | |
| Payroll taxes | $2,080,613 | $1,768,521 | $249,674 | $62,418 | 2.4% | |
| Information technology | $1,816,852 | $1,574,269 | $210,635 | $31,948 | 2.1% | |
| Fees: other services | $1,396,426 | $1,062,049 | $204,569 | $129,808 | 1.6% | |
| Advertising and promotion | $1,286,713 | $1,153,905 | $116,430 | $16,378 | 1.5% | |
| Grants outside the US | $911,600 | $911,600 | - | - | 1.1% | |
| Travel | $772,980 | $546,792 | $134,191 | $91,997 | 0.9% | |
| Fees: legal | $652,931 | - | $652,931 | - | 0.8% | |
| All other expenses | $441,100 | $174,755 | $301,116 | -$34,771 | 0.5% | |
| Interest | $367,884 | - | $367,884 | - | 0.4% | |
| Insurance | $310,141 | $286,143 | $22,827 | $1,171 | 0.4% | |
| Fees: accounting | $286,906 | - | $286,906 | - | 0.3% | |
| Office expenses | $254,217 | $220,275 | $29,472 | $4,470 | 0.3% | |
| Conferences, conventions and meetings | $128,753 | $52,149 | $72,701 | $3,903 | 0.1% | |
| Pay: disqualified persons | $104,309 | $88,663 | $13,560 | $2,086 | 0.1% | |
| Other (as described) | DUES | $82,299 | $1,133 | $75,952 | $5,214 | 0.1% |
| Fees: investment management | $40,260 | $40,260 | - | - | 0.0% | |
| Other (as described) | UBI TAXES | $13,090 | - | $13,090 | - | 0.0% |
| Total | $85,939,425 | 100% |
2020 · Form 990 · $81,170,041 spent · pay $36,998,175 · grants $1,119,601 · events $65,883
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $26,753,215 | $22,671,916 | $3,457,725 | $623,574 | 33.0% | |
| Other (as described) | Lab Supplies Service | $11,986,207 | $11,912,973 | $73,234 | - | 14.8% |
| Other (as described) | Consortium | $9,651,554 | $9,651,554 | - | - | 11.9% |
| Occupancy | $8,351,070 | $7,569,655 | $741,359 | $40,056 | 10.3% | |
| Depreciation and depletion | $4,108,625 | $4,108,625 | - | - | 5.1% | |
| Other employee benefits | $3,601,129 | $3,033,690 | $468,255 | $99,184 | 4.4% | |
| Pension plan contributions | $2,750,051 | $2,355,512 | $326,312 | $68,227 | 3.4% | |
| Payroll taxes | $1,954,141 | $1,673,788 | $231,872 | $48,481 | 2.4% | |
| Pay: officers, directors, trustees, key employees | $1,939,639 | $1,640,307 | $253,383 | $45,949 | 2.4% | |
| Information technology | $1,911,754 | $1,810,526 | $91,909 | $9,319 | 2.4% | |
| Other (as described) | Manuscripts Costs | $1,876,795 | $774,294 | $1,065,329 | $37,172 | 2.3% |
| Other (as described) | Other Expenses | $1,606,313 | $1,595,188 | $11,125 | - | 2.0% |
| Grants outside the US | $1,091,606 | $1,091,606 | - | - | 1.3% | |
| Fees: other services | $949,356 | $793,871 | $90,174 | $65,311 | 1.2% | |
| Fees: legal | $847,522 | $104,921 | $742,601 | - | 1.0% | |
| Advertising and promotion | $679,769 | $366,669 | $307,844 | $5,256 | 0.8% | |
| Fees: accounting | $401,864 | - | $401,864 | - | 0.5% | |
| Insurance | $287,102 | $260,113 | $25,604 | $1,385 | 0.4% | |
| Travel | $188,406 | $174,129 | $8,669 | $5,608 | 0.2% | |
| Office expenses | $140,045 | $63,981 | $39,965 | $36,099 | 0.2% | |
| Conferences, conventions and meetings | $65,883 | $45,217 | $17,786 | $2,880 | 0.1% | |
| Grants to US organizations and governments | $27,995 | $27,995 | - | - | 0.0% | |
| Total | $81,170,041 | 100% |
2019 · Form 990 · $70,159,237 spent · pay $34,553,331 · grants $769,190 · events $211,092
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $24,931,232 | $21,075,216 | $3,394,139 | $461,877 | 35.5% | |
| Other (as described) | Lab Supplies Service | $10,015,899 | $10,015,899 | - | - | 14.3% |
| Occupancy | $7,137,151 | $6,479,208 | $623,523 | $34,420 | 10.2% | |
| Other (as described) | Consortium | $6,021,321 | $6,021,321 | - | - | 8.6% |
| Other employee benefits | $3,322,820 | $2,861,979 | $379,780 | $81,061 | 4.7% | |
| Pension plan contributions | $2,572,417 | $2,155,532 | $358,357 | $58,528 | 3.7% | |
| Other (as described) | Other Expenses | $2,170,425 | $2,170,425 | - | - | 3.1% |
| Depreciation and depletion | $1,886,851 | $1,758,919 | $127,932 | - | 2.7% | |
| Payroll taxes | $1,822,982 | $1,527,551 | $253,955 | $41,476 | 2.6% | |
| Other (as described) | Manuscripts Costs | $1,693,741 | $1,200,978 | $433,686 | $59,077 | 2.4% |
| Information technology | $1,682,425 | $565,763 | $1,107,760 | $8,902 | 2.4% | |
| Pay: officers, directors, trustees, key employees | $1,666,808 | $1,414,208 | $216,919 | $35,681 | 2.4% | |
| All other expenses | $1,190,726 | $1,078,222 | $112,504 | - | 1.7% | |
| Fees: legal | $837,238 | $572,941 | $264,297 | - | 1.2% | |
| Grants outside the US | $750,181 | $750,181 | - | - | 1.1% | |
| Travel | $728,607 | $570,409 | $126,833 | $31,365 | 1.0% | |
| Fees: other services | $327,513 | $67,222 | $181,085 | $79,206 | 0.5% | |
| Fees: accounting | $312,402 | - | $312,402 | - | 0.4% | |
| Advertising and promotion | $246,802 | $6,361 | $238,855 | $1,586 | 0.4% | |
| Pay: disqualified persons | $237,072 | $201,156 | $35,916 | - | 0.3% | |
| Insurance | $219,493 | $202,123 | $16,275 | $1,095 | 0.3% | |
| Conferences, conventions and meetings | $211,092 | $176,687 | $25,546 | $8,859 | 0.3% | |
| Office expenses | $155,030 | $107,069 | $29,477 | $18,484 | 0.2% | |
| Grants to US organizations and governments | $19,009 | $19,009 | - | - | 0.0% | |
| Total | $70,159,237 | 100% |
2017 · Form 990 · $58,276,909 spent · pay $30,484,441 · grants $7,000 · events $197,174
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $22,233,965 | $19,404,728 | $2,767,840 | $61,397 | 38.2% | |
| Other (as described) | Lab Supplies & Svcs | $8,001,470 | $7,820,288 | $181,182 | - | 13.7% |
| Occupancy | $6,336,188 | $5,639,207 | $696,981 | - | 10.9% | |
| Other (as described) | Consortiums | $5,564,371 | $5,564,371 | - | - | 9.5% |
| Other employee benefits | $2,828,982 | $2,405,140 | $391,910 | $31,932 | 4.9% | |
| Pension plan contributions | $2,234,805 | $1,949,867 | $277,116 | $7,822 | 3.8% | |
| Depreciation and depletion | $1,701,880 | $1,701,880 | - | - | 2.9% | |
| Pay: officers, directors, trustees, key employees | $1,608,747 | $1,415,697 | $167,064 | $25,986 | 2.8% | |
| Payroll taxes | $1,577,942 | $1,376,754 | $195,665 | $5,523 | 2.7% | |
| Other (as described) | Manuscripts Cost | $1,338,350 | $601,713 | $598,813 | $137,824 | 2.3% |
| Information technology | $1,121,151 | $828,299 | $285,670 | $7,182 | 1.9% | |
| Fees: other services | $937,156 | $215,546 | $346,748 | $374,862 | 1.6% | |
| All other expenses | $699,801 | $397,525 | $302,276 | - | 1.2% | |
| Travel | $670,522 | $582,972 | $66,928 | $20,622 | 1.2% | |
| Fees: legal | $418,176 | $372,177 | $45,999 | - | 0.7% | |
| Insurance | $246,819 | $242,806 | $4,013 | - | 0.4% | |
| Fees: accounting | $205,393 | - | $205,393 | - | 0.4% | |
| Conferences, conventions and meetings | $197,174 | $170,656 | $21,689 | $4,829 | 0.3% | |
| Office expenses | $159,447 | $123,690 | $9,432 | $26,325 | 0.3% | |
| Advertising and promotion | $135,541 | $5,051 | $130,490 | - | 0.2% | |
| Other (as described) | UBIT taxes | $52,029 | - | $52,029 | - | 0.1% |
| Grants to US organizations and governments | $7,000 | $7,000 | - | - | 0.0% | |
| Total | $58,276,909 | 100% |
2016 · Form 990 · $57,981,481 spent · pay $27,887,172 · grants $10,000 · events $213,933
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $20,355,338 | $17,761,181 | $2,521,706 | $72,451 | 35.1% | |
| Other (as described) | Lab Supplies & Svcs | $8,948,444 | $8,759,879 | $188,565 | - | 15.4% |
| Occupancy | $7,176,447 | $5,806,470 | $1,369,977 | - | 12.4% | |
| Other (as described) | Consortiums | $6,142,311 | $6,142,311 | - | - | 10.6% |
| Other employee benefits | $2,508,880 | $2,269,713 | $225,928 | $13,239 | 4.3% | |
| Pension plan contributions | $2,041,746 | $1,781,423 | $253,177 | $7,146 | 3.5% | |
| Depreciation and depletion | $1,796,573 | $1,796,573 | - | - | 3.1% | |
| Other (as described) | Manuscripts Cost | $1,523,261 | $621,431 | $803,533 | $98,297 | 2.6% |
| Pay: officers, directors, trustees, key employees | $1,498,231 | $1,318,443 | $152,733 | $27,055 | 2.6% | |
| Payroll taxes | $1,482,977 | $1,293,898 | $183,889 | $5,190 | 2.6% | |
| All other expenses | $981,200 | $355,721 | $625,479 | - | 1.7% | |
| Information technology | $913,217 | $361,965 | $543,900 | $7,352 | 1.6% | |
| Travel | $607,952 | $512,642 | $62,720 | $32,590 | 1.0% | |
| Fees: other services | $591,991 | $31,825 | $286,292 | $273,874 | 1.0% | |
| Fees: legal | $401,652 | $399,980 | $1,672 | - | 0.7% | |
| Insurance | $216,334 | $212,320 | $4,014 | - | 0.4% | |
| Conferences, conventions and meetings | $213,933 | $189,646 | $20,327 | $3,960 | 0.4% | |
| Office expenses | $205,154 | $161,805 | $19,419 | $23,930 | 0.4% | |
| Fees: accounting | $195,454 | - | $195,454 | - | 0.3% | |
| Advertising and promotion | $145,732 | $6,287 | $139,445 | - | 0.3% | |
| Other (as described) | UBIT Taxes | $24,654 | - | $24,654 | - | 0.0% |
| Grants to US organizations and governments | $10,000 | $10,000 | - | - | 0.0% | |
| Total | $57,981,481 | 100% |
2015 · Form 990 · $52,815,911 spent · pay $26,065,694 · grants $3,000 · events $178,995
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $18,920,904 | $16,648,088 | $2,251,648 | $21,168 | 35.8% | |
| Other (as described) | LAB SUPPLIES & SVCS | $8,245,061 | $8,218,661 | $26,400 | - | 15.6% |
| Occupancy | $6,352,915 | $5,740,171 | $612,744 | - | 12.0% | |
| Other (as described) | CONSORTIUMS | $5,312,203 | $5,312,203 | - | - | 10.1% |
| Other employee benefits | $2,385,653 | $2,077,781 | $301,103 | $6,769 | 4.5% | |
| Depreciation and depletion | $2,020,752 | $2,020,752 | - | - | 3.8% | |
| Pension plan contributions | $1,940,168 | $1,744,017 | $194,017 | $2,134 | 3.7% | |
| Pay: officers, directors, trustees, key employees | $1,429,590 | $1,258,039 | $145,174 | $26,377 | 2.7% | |
| Payroll taxes | $1,389,379 | $1,248,913 | $138,938 | $1,528 | 2.6% | |
| Other (as described) | PAGE AND MANUSCRIPTS CO | $1,069,659 | $472,094 | $524,421 | $73,144 | 2.0% |
| Information technology | $986,113 | $295,163 | $686,423 | $4,527 | 1.9% | |
| Other (as described) | MINOR EQUIPMENT | $709,254 | $541,768 | $167,486 | - | 1.3% |
| Travel | $497,213 | $425,099 | $31,601 | $40,513 | 0.9% | |
| Fees: legal | $290,524 | $248,355 | $42,169 | - | 0.6% | |
| Advertising and promotion | $207,396 | $9,210 | $197,696 | $490 | 0.4% | |
| Fees: other services | $199,407 | - | $199,407 | - | 0.4% | |
| Insurance | $191,296 | $187,281 | $4,015 | - | 0.4% | |
| Fees: accounting | $190,627 | - | $190,627 | - | 0.4% | |
| Conferences, conventions and meetings | $178,995 | $146,778 | $29,163 | $3,054 | 0.3% | |
| Office expenses | $165,947 | $105,694 | $36,492 | $23,761 | 0.3% | |
| All other expenses | $119,265 | - | $119,265 | - | 0.2% | |
| Fees: professional fundraisers | $9,405 | - | - | $9,405 | 0.0% | |
| Grants to US organizations and governments | $3,000 | $3,000 | - | - | 0.0% | |
| Fees: lobbying | $1,185 | - | $1,185 | - | 0.0% | |
| Total | $52,815,911 | 100% |
2014 · Form 990 · $51,646,368 spent · pay $26,674,436 · grants $0 · events $102,840
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $19,431,621 | $17,154,919 | $2,253,854 | $22,848 | 37.6% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $7,759,952 | $7,737,199 | $22,753 | $0 | 15.0% |
| Occupancy | $5,391,446 | $4,661,977 | $703,259 | $26,210 | 10.4% | |
| Other (as described) | CONSORTIUMS | $4,086,348 | $4,086,348 | $0 | $0 | 7.9% |
| Other employee benefits | $2,499,391 | $2,218,215 | $276,935 | $4,241 | 4.8% | |
| Depreciation and depletion | $2,132,160 | $2,130,257 | $1,903 | - | 4.1% | |
| Pension plan contributions | $2,031,963 | $1,825,516 | $203,196 | $3,251 | 3.9% | |
| Payroll taxes | $1,448,146 | $1,301,051 | $144,813 | $2,282 | 2.8% | |
| Pay: officers, directors, trustees, key employees | $1,263,315 | $1,111,717 | $146,557 | $5,041 | 2.4% | |
| Other (as described) | RESEARCH CONSULTANT | $1,238,003 | $859,544 | $361,551 | $16,908 | 2.4% |
| Other (as described) | MINOR EQUIPMENT | $871,756 | $344,533 | $527,223 | $0 | 1.7% |
| Information technology | $607,255 | $304,954 | $298,255 | $4,046 | 1.2% | |
| Insurance | $524,824 | $524,824 | - | - | 1.0% | |
| Travel | $496,332 | $400,422 | $16,004 | $79,906 | 1.0% | |
| Fees: accounting | $451,692 | $199,014 | $252,678 | - | 0.9% | |
| All other expenses | $427,171 | $173,004 | $241,456 | $12,711 | 0.8% | |
| Fees: legal | $338,149 | $140,820 | $197,329 | - | 0.7% | |
| Fees: other services | $211,607 | - | $6,496 | $205,111 | 0.4% | |
| Office expenses | $154,483 | $91,700 | $41,164 | $21,619 | 0.3% | |
| Advertising and promotion | $112,277 | $98,599 | $13,678 | - | 0.2% | |
| Conferences, conventions and meetings | $102,840 | $97,208 | $3,500 | $2,132 | 0.2% | |
| Fees: professional fundraisers | $61,725 | - | - | $61,725 | 0.1% | |
| Fees: lobbying | $3,912 | - | $3,912 | - | 0.0% | |
| Total | $51,646,368 | 100% |
2013 · Form 990 · $52,043,703 spent · pay $27,545,725 · grants $4,700 · events $174,853
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $19,875,450 | $16,738,162 | $3,109,684 | $27,604 | 38.2% | |
| Other (as described) | LAB SUPPLIES & SVCS | $8,328,378 | $8,284,744 | $43,634 | - | 16.0% |
| Occupancy | $5,276,814 | $4,833,941 | $442,742 | $131 | 10.1% | |
| Other (as described) | CONSORTIUMS | $4,596,648 | $4,596,648 | - | - | 8.8% |
| Other employee benefits | $2,646,415 | $2,331,654 | $308,229 | $6,532 | 5.1% | |
| Depreciation and depletion | $2,060,042 | $1,913,671 | $146,371 | - | 4.0% | |
| Pension plan contributions | $1,971,517 | $1,657,789 | $310,968 | $2,760 | 3.8% | |
| Payroll taxes | $1,531,690 | $1,312,080 | $217,678 | $1,932 | 2.9% | |
| Pay: officers, directors, trustees, key employees | $1,520,653 | $1,338,175 | $177,562 | $4,916 | 2.9% | |
| All other expenses | $818,317 | $365,351 | $406,994 | $45,972 | 1.6% | |
| Other (as described) | MINOR EQUIPMENT | $611,970 | $428,196 | $183,774 | - | 1.2% |
| Information technology | $584,029 | $292,134 | $283,564 | $8,331 | 1.1% | |
| Travel | $407,537 | $364,711 | $7,290 | $35,536 | 0.8% | |
| Fees: professional fundraisers | $359,634 | - | - | $359,634 | 0.7% | |
| Other (as described) | RESEARCH CONSULTANT | $260,378 | $260,378 | - | - | 0.5% |
| Fees: legal | $236,135 | $234,233 | $1,902 | - | 0.5% | |
| Advertising and promotion | $232,054 | $7,215 | $197,951 | $26,888 | 0.4% | |
| Insurance | $183,194 | $164,146 | $19,048 | - | 0.4% | |
| Fees: accounting | $183,003 | - | $183,003 | - | 0.4% | |
| Conferences, conventions and meetings | $174,853 | $166,293 | $6,181 | $2,379 | 0.3% | |
| Office expenses | $168,726 | $97,697 | $49,035 | $21,994 | 0.3% | |
| Fees: other services | $6,365 | - | $6,365 | - | 0.0% | |
| Fees: lobbying | $5,201 | - | $5,201 | - | 0.0% | |
| Grants to US organizations and governments | $4,700 | $4,700 | - | - | 0.0% | |
| Total | $52,043,703 | 100% |
2012 · Form 990 · $48,077,169 spent · pay $25,931,888 · grants $4,900 · events $208,266
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $18,086,198 | $15,656,481 | $2,403,119 | $26,598 | 37.6% | |
| Other (as described) | LAB SUPPLIES | $8,026,429 | $8,017,565 | $8,864 | $0 | 16.7% |
| Occupancy | $4,963,458 | $4,533,575 | $415,202 | $14,681 | 10.3% | |
| Other employee benefits | $2,995,830 | $2,491,874 | $501,297 | $2,659 | 6.2% | |
| Other (as described) | CONSORTIUM | $2,847,738 | $2,847,738 | - | $0 | 5.9% |
| Depreciation and depletion | $1,965,589 | $1,844,940 | $120,649 | - | 4.1% | |
| Pension plan contributions | $1,792,698 | $1,545,124 | $243,942 | $3,632 | 3.7% | |
| Pay: officers, directors, trustees, key employees | $1,466,841 | $1,290,820 | $171,259 | $4,762 | 3.1% | |
| Payroll taxes | $1,296,625 | $1,141,031 | $152,934 | $2,660 | 2.7% | |
| All other expenses | $806,963 | $548,565 | $242,484 | $15,914 | 1.7% | |
| Information technology | $687,069 | $418,592 | $265,878 | $2,599 | 1.4% | |
| Advertising and promotion | $630,710 | $47,401 | $510,379 | $72,930 | 1.3% | |
| Other (as described) | MINOR EQUIPMENT | $459,420 | $420,875 | $38,545 | $0 | 1.0% |
| Pay: disqualified persons | $293,696 | $293,696 | - | - | 0.6% | |
| Fees: professional fundraisers | $245,000 | - | - | $245,000 | 0.5% | |
| Fees: legal | $233,461 | $192,485 | $40,976 | - | 0.5% | |
| Office expenses | $228,948 | $194,247 | $32,662 | $2,039 | 0.5% | |
| Travel | $214,959 | $207,792 | $7,167 | - | 0.4% | |
| Conferences, conventions and meetings | $208,266 | $195,718 | $12,030 | $518 | 0.4% | |
| Fees: accounting | $174,443 | - | $174,443 | - | 0.4% | |
| Insurance | $159,594 | $144,372 | $15,222 | - | 0.3% | |
| Other (as described) | RESEARCH CONSULTANT FEE | $150,274 | $150,274 | - | - | 0.3% |
| Fees: other services | $134,340 | $78,075 | $56,265 | - | 0.3% | |
| Grants to US organizations and governments | $4,900 | $4,900 | - | - | 0.0% | |
| Fees: lobbying | $3,720 | - | $3,720 | - | 0.0% | |
| Total | $48,077,169 | 100% |
2011 · Form 990 · $46,314,239 spent · pay $24,872,839 · grants $0 · events $128,992
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $17,575,910 | $14,952,781 | $2,549,777 | $73,352 | 37.9% | |
| Other (as described) | LAB SUPPLIES | $7,858,461 | $7,845,456 | $13,005 | $0 | 17.0% |
| Occupancy | $4,845,281 | $4,422,276 | $403,127 | $19,878 | 10.5% | |
| Other (as described) | CONSORTIUM | $3,543,270 | $3,543,270 | $0 | $0 | 7.7% |
| Other employee benefits | $2,496,930 | $2,048,251 | $443,679 | $5,000 | 5.4% | |
| Depreciation and depletion | $1,705,284 | $1,563,404 | $141,880 | - | 3.7% | |
| Pension plan contributions | $1,690,573 | $1,497,683 | $182,865 | $10,025 | 3.7% | |
| Pay: officers, directors, trustees, key employees | $1,601,236 | $1,384,151 | $188,312 | $28,773 | 3.5% | |
| Payroll taxes | $1,279,336 | $1,141,382 | $127,934 | $10,020 | 2.8% | |
| All other expenses | $810,084 | $564,232 | $229,609 | $16,243 | 1.7% | |
| Information technology | $527,202 | $285,914 | $239,168 | $2,120 | 1.1% | |
| Other (as described) | MINOR EQUIPMENT | $382,140 | $350,382 | $31,758 | $0 | 0.8% |
| Advertising and promotion | $350,204 | $62,532 | $217,226 | $70,446 | 0.8% | |
| Travel | $316,430 | $286,045 | $26,930 | $3,455 | 0.7% | |
| Pay: disqualified persons | $228,854 | $228,854 | - | - | 0.5% | |
| Fees: other services | $228,299 | $80,059 | $148,240 | - | 0.5% | |
| Office expenses | $197,365 | $159,160 | $37,153 | $1,052 | 0.4% | |
| Fees: accounting | $182,715 | - | $182,715 | - | 0.4% | |
| Fees: legal | $180,197 | $78,318 | $101,879 | - | 0.4% | |
| Insurance | $158,022 | $143,041 | $14,981 | - | 0.3% | |
| Conferences, conventions and meetings | $87,602 | $73,362 | $12,027 | $2,213 | 0.2% | |
| Other (as described) | PAGECOSTS/MANUSCRIPT HA | $65,124 | $65,124 | - | - | 0.1% |
| Fees: lobbying | $3,720 | - | $3,720 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $41,390 | reported apart | |||
| Total | $46,314,239 | 100% |
2010 · Form 990 · $45,816,501 spent · pay $24,616,497 · grants $2,500 · events $106,937
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $17,446,354 | $14,966,821 | $2,412,289 | $67,244 | 38.1% | |
| Other (as described) | LAB SUPPLIES | $7,209,276 | $7,193,402 | $15,874 | - | 15.7% |
| Occupancy | $4,745,590 | $4,289,767 | $431,007 | $24,816 | 10.4% | |
| Other (as described) | CONSORTIUM EXPENSE | $4,121,876 | $4,121,876 | - | - | 9.0% |
| Other employee benefits | $2,412,457 | $2,054,536 | $345,282 | $12,639 | 5.3% | |
| Pay: officers, directors, trustees, key employees | $1,627,521 | $1,432,219 | $162,752 | $32,550 | 3.6% | |
| Pension plan contributions | $1,518,369 | $1,354,532 | $151,837 | $12,000 | 3.3% | |
| Payroll taxes | $1,408,268 | $1,239,276 | $140,827 | $28,165 | 3.1% | |
| Depreciation and depletion | $1,385,225 | $1,211,842 | $173,383 | - | 3.0% | |
| All other expenses | $947,314 | $702,227 | $225,647 | $19,440 | 2.1% | |
| Information technology | $588,568 | $299,868 | $285,355 | $3,345 | 1.3% | |
| Other (as described) | MINOR EQUIP & FURNITURE | $474,333 | $431,026 | $43,307 | - | 1.0% |
| Travel | $341,638 | $323,515 | $16,890 | $1,233 | 0.7% | |
| Advertising and promotion | $249,754 | $10,156 | $152,848 | $86,750 | 0.5% | |
| Office expenses | $204,167 | $168,559 | $34,554 | $1,054 | 0.4% | |
| Pay: disqualified persons | $203,528 | $203,528 | - | - | 0.4% | |
| Fees: legal | $184,928 | $80,376 | $104,552 | - | 0.4% | |
| Fees: accounting | $163,837 | - | $163,837 | - | 0.4% | |
| Fees: other services | $152,353 | $84,321 | $68,032 | - | 0.3% | |
| Insurance | $140,633 | $124,158 | $16,475 | - | 0.3% | |
| Conferences, conventions and meetings | $106,937 | $94,502 | $11,036 | $1,399 | 0.2% | |
| Other (as described) | PAGE COSTS/MANUSCRIPT H | $96,535 | $96,535 | - | - | 0.2% |
| Other (as described) | RELOCATION/RECRUITMENT | $80,840 | $80,840 | - | - | 0.2% |
| Fees: lobbying | $3,700 | - | $3,700 | - | 0.0% | |
| Grants to US organizations and governments | $2,500 | $2,500 | - | - | 0.0% | |
| Total | $45,816,501 | 100% |
Federal grants and contracts
Awards from USAspending.gov to a recipient with this organization's name and zip code. Obligations by federal fiscal year (October to September); each award links to its page on usaspending.gov.
| Fiscal year | Grants and other assistance | Contracts | Awards |
|---|---|---|---|
| 2026 | $27,199,495 | $6,527,367 | 49 |
| 2025 | $26,007,183 | $5,239,657 | 48 |
| 2024 | $56,740,486 | $5,983,184 | 49 |
| 2023 | $32,857,885 | $6,145,192 | 47 |
| 2022 | $40,958,943 | $8,062,902 | 62 |
| 2021 | $46,005,285 | $7,477,898 | 61 |
| 2020 | $47,425,022 | $6,899,305 | 65 |
| 2019 | $39,333,691 | $5,855,665 | 70 |
| 2018 | $32,858,178 | $4,920,481 | 66 |
| 2017 | $27,861,422 | $3,906,910 | 66 |
| 2016 | $0 | $4,056,364 | 3 |
| 2015 | $0 | $3,724,552 | 2 |
| 2014 | $0 | $8,719,139 | 6 |
| 2013 | $0 | $3,310,469 | 3 |
| 2012 | $0 | $5,980,859 | 8 |
| 2011 | $0 | $1,570,179 | 3 |
| 2010 | $0 | $1,241,739 | 1 |
| 2009 | $0 | $16,681,277 | 4 |
| 2007 | $263,311 | $2,389,948 | 2 |
Largest awards · 200 shown
| Year | Agency | Kind | Program | Description | Obligated |
|---|---|---|---|---|---|
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HIPC DATA COORDINATING CENTER - PROJECT SUMMARY/ABSTRACT THE HUMAN IMMUNOLOGY PROJECT CONSORTIUM (HIPC) WAS FOUNDED IN 2010 TO CREATE A NETWORK OF INDEPENDENT C | $3,919,744 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM | $3,576,859 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FUNCTIONAL AND DYSFUNCTIONAL HUMAN CD4 T CELL AND B CELL RESPONSES TO BACTERIA AND VIRUSES | $2,573,442 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HUMAN IMMUNE SIGNATURES OF DENGUE VIRUS AND MYCOBACTERIUM TUBERCULOSIS EXPOSURE IN INFECTION, DISEASE AND VACCINATION | $2,391,540 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | RESEARCH RESOURCES: EPIGENOMIC AND TRANSCRIPTOMIC PROFILES OF HUMAN IMMUNE CELLS | $1,301,799 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TOWARDS A PREDICTIVE UNDERSTANDING OF INFLUENZA IMMUNITY THROUGH EXPERIMENTAL DATA INTEGRATION, ITERATIVE MODEL DEVELOPMENT, AND RIGOROUS ASSESSMENT OF MODEL QU | $1,246,617 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | IDENTIFICATION AND CHARACTERIZATION OF T CELL EPITOPES FROM BACTERIAL PATHOGENS CAUSING PNEUMONIA | $1,125,516 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | THE IDENTIFICATION AND VALIDATION OF EPITOPES CONSERVED IN VIRAL PATHOGEN FAMILIES WITH PANDEMIC POTENTIAL | $1,124,993 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TET ENZYMES AS GUARDIANS OF GENOME STABILITY | $1,098,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MAXIMIZING GERMINAL CENTERS AND SOMATIC HYPERMUTATION TO HIV ENV IMMUNOGENS - ABSTRACT WE PROPOSE THAT THE FEATURES OF GERMINAL CENTER BIOLOGY IMPORTANT FOR DEV | $959,683 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | ROLE OF MAIT CELLS IN PRIMARY BILIARY CHOLANGITIS. - PROJECT SUMMARY PRIMARY BILIARY CHOLANGITIS (PBC; PREVIOUSLY CALLED PRIMARY BILIARY CIRRHOSIS) IS AN AUTOIM | $939,776 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | BZIP PROTEINS, NFAT, AND LYMPHOCYTE GENE INDUCTION | $929,885 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | UNDERSTANDING LYMPHOID TISSUE IMMUNOLOGY IN HUMAN SLE AND THE IMPACT OF THERAPEUTIC INTERVENTIONS - PROJECT SUMMARY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IS A COMP | $929,095 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPMENT OF A THERAPEUTIC ANTIBODY COCKTAIL AGAINST NEW WORLD ARENAVIRUSES - PROJECT SUMMARY/ABSTRACT THE MAMMARENAVIRUS GENUS OF THE ARENAVIRIDAE FAMILY, EN | $923,708 |
| 2026 | National Institutes of Health | Grant or other assistance | RESEARCH INFRASTRUCTURE PROGRAMS 93.351 | NEXT GENERATION CRISPR READY, HLA CLASS I AND II TRANSGENIC MOUSE PLATFORM - ABSTRACT T CELL RESPONSES ARE CRITICAL IN THE PATHOGENESIS, PREVENTION, AND TREATME | $911,668 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ILLUMINATING IMMUNOREGULATORY MECHANISMS OF INTERLEUKIN-1 RECEPTOR 8 AND NOVEL THERAPEUTIC STRATEGIES - PROJECT SUMMARY AS A KEY IMMUNE RESPONSE, INFLAMMATION U | $890,877 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | A NOVEL STRATEGY FOR VACCINE-INDUCED PROTECTION AGAINST MATERNAL-TO-FETAL TRANSMISSION OF ZIKA VIRUS - PROJECT SUMMARY THE LONG-TERM GOAL OF THIS PROJECT IS TO | $873,282 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HIV MRNA VACCINE STRATEGIES FOR EFFICIENT PRIMING, DIVERSITY AND DURABILITY OF IMMUNE RESPONSES - SUMMARY CONVENTIONAL VACCINE STRATEGIES HAVE NOT INDUCED SUCCE | $829,725 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE - PROJECT SUMMARY/ABSTRACT CANCER EPITOPES ARE UNIQUE MOLECULAR SIGNATURES EXPRESSED BY TUMOR CELLS AND RECOGN | $785,938 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DIETARY ENVIRONMENTAL CONTROL OF ENTERIC T CELL IMMUNITY - SUMMARY ABSTRACT NUTRITION HAS A SIGNIFICANT IMPACT ON IMMUNE HEALTH, YET MECHANISTIC INSIGHTS ARE LA | $776,314 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HOUSE DUST-MITE ALLERGEN-SPECIFIC T CELL SUBSETS IN ALLERGY AND ASTHMA - PROJECT SUMMARY ONE THIRD OF THE POPULATION SUFFER FROM ALLERGIC DISEASES INCLUDING AST | $764,868 |
| 2026 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | IGF::OT::IGF IMMUNE EPITOPE AND ANALYSIS PROGRAM | $699,999 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DYSREGULATION OF TET DIOXYGENASE FUNCTION AS A SOURCE OF ABERRANT TRANSPOSABLE ELEMENT EXPRESSION DURING HUMAN AGING - ABSTRACT IT IS WELL ESTABLISHED THAT AGIN | $658,800 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEORPHANIZING A NOVEL GPCR EXPRESSED BY TISSUE RESIDENT MEMORY CELLS - PROJECT SUMMARY LUNG INFECTIONS REMAIN A SIGNIFICANT SOURCE OF MORBIDITY AND MORTALITY AC | $566,875 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | PROTEOME-WIDE BASE EDITOR SCREENS TO ASSESS PHOSPHORYLATION SITE FUNCTIONALITY IN IMMUNOSENESCENCE - ABSTRACT WE OFTEN DEPICT SIGNALING PATHWAYS BY A DOZEN OR S | $559,601 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DEFINING INTERACTION QUANTITATIVE TRAIT LOCI (IQTLS) IN THE HUMAN GENOME | $494,100 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEFINING FUNCTION AND REGULATION OF THE NOVEL SLE-SUSCEPTIBILITY GENE ILRUN IN T CELLS - PROJECT SUMMARY/ABSTRACT SYSTEMIC LUPUS ERYTHEMATOUS (SLE) CAUSES SUBST | $476,436 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ELUCIDATING THE SIGNALING AND PROTEIN INTERACTION NETWORKS OF THE O-GLCNAC TRANSFERASE DURING EMBRYONIC STEM CELL STATE TRANSITIONS - PROJECT SUMMARY/ABSTRACT O | $457,500 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | GENETIC STUDIES LINKING LSP1 FUNCTION IN T CELLS TO INFLAMMATORY BOWEL DISEASE - PROJECT SUMMARY/ABSTRACT INFLAMMATORY BOWEL DISEASES (IBD) CAUSE SUBSTANTIAL MO | $402,600 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MAPPING ANTI-FILOVIRUS HUMORAL IMMUNE RESPONSES IN BROADLY SEROREACTIVE INDIVIDUALS - PROJECT SUMMARY/ABSTRACT: FILOVIRUSES ENCOMPASS A BROAD GROUP OF HIGHLY LE | $279,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MAPPING THE HUMORAL IMMUNE RESPONSE TO THE SURFACE GLYCOPROTEINS OF THE MUMPS VIRUS - ABSTRACT MUMPS VIRUS IS ONE COMPONENT OF THE MMR VACCINE, WHICH HAS BEEN | $279,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HUMAN UPPER AIRWAY IMMUNE MEMORY KINETICS AND DURABILITY AGAINST RESPIRATORY PATHOGENS - PROJECT SUMMARY PERIPHERAL BLOOD IS THE PRIMARY SAMPLE TYPE COLLECTED | $159,300 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CONSORTIUM FOR IMMUNOTHERAPEUTICS AGAINST EMERGING VIRAL THREATS | -$179,677 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HIPC DATA COORDINATING CENTER - PROJECT SUMMARY/ABSTRACT THE HUMAN IMMUNOLOGY PROJECT CONSORTIUM (HIPC) WAS FOUNDED IN 2010 TO CREATE A NETWORK OF INDEPENDENT C | $3,922,735 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | IGF::OT::IGF IMMUNE EPITOPE AND ANALYSIS PROGRAM | $3,327,747 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FUNCTIONAL AND DYSFUNCTIONAL HUMAN CD4 T CELL AND B CELL RESPONSES TO BACTERIA AND VIRUSES | $2,576,765 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HUMAN IMMUNE SIGNATURES OF DENGUE VIRUS AND MYCOBACTERIUM TUBERCULOSIS EXPOSURE IN INFECTION, DISEASE AND VACCINATION | $2,391,539 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SIGNAL TRANSDUCTION AND GENE INDUCTION IN T LYMPHOCYTES | $1,976,400 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | RESEARCH RESOURCES: EPIGENOMIC AND TRANSCRIPTOMIC PROFILES OF HUMAN IMMUNE CELLS | $1,301,799 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TOWARDS A PREDICTIVE UNDERSTANDING OF INFLUENZA IMMUNITY THROUGH EXPERIMENTAL DATA INTEGRATION, ITERATIVE MODEL DEVELOPMENT, AND RIGOROUS ASSESSMENT OF MODEL QU | $1,246,617 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TET ENZYMES AS GUARDIANS OF GENOME STABILITY | $1,098,000 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EPIGENETIC CONTROL OF FOXP3 EXPRESSION IN INDUCED T REGULATORY CELLS | $1,098,000 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | IDENTIFICATION AND CHARACTERIZATION OF T CELL EPITOPES FROM BACTERIAL PATHOGENS CAUSING PNEUMONIA | $956,427 |
| 2025 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | THE IDENTIFICATION AND VALIDATION OF EPITOPES CONSERVED IN VIRAL PATHOGEN FAMILIES WITH PANDEMIC POTENTIAL | $955,483 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MAXIMIZING GERMINAL CENTERS AND SOMATIC HYPERMUTATION TO HIV ENV IMMUNOGENS - ABSTRACT WE PROPOSE THAT THE FEATURES OF GERMINAL CENTER BIOLOGY IMPORTANT FOR DEV | $874,385 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HIV MRNA VACCINE STRATEGIES FOR EFFICIENT PRIMING, DIVERSITY AND DURABILITY OF IMMUNE RESPONSES - SUMMARY CONVENTIONAL VACCINE STRATEGIES HAVE NOT INDUCED SUCCE | $874,358 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | A NOVEL STRATEGY FOR VACCINE-INDUCED PROTECTION AGAINST MATERNAL-TO-FETAL TRANSMISSION OF ZIKA VIRUS - PROJECT SUMMARY THE LONG-TERM GOAL OF THIS PROJECT IS TO | $873,588 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE - ABSTRACT RECENT YEARS HAVE WITNESSED A DRAMATIC RISE IN INTEREST TOWARDS CANCER EPITOPES IN GENERAL, AND NEO | $851,522 |
| 2025 | National Institutes of Health | Grant or other assistance | RESEARCH INFRASTRUCTURE PROGRAMS 93.351 | NEXT GENERATION CRISPR READY, HLA CLASS I AND II TRANSGENIC MOUSE PLATFORM - ABSTRACT T CELL RESPONSES ARE CRITICAL IN THE PATHOGENESIS, PREVENTION, AND TREATME | $775,888 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPMENT OF A REPLICON RNA-BASED VACCINE AGAINST DENGUE AND ZIKA - ABSTRACT THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP A DENGUE-ZIKA VACCINE THAT PROVI | $721,849 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | BIOACTIVE METABOLITES MODULATE IMMUNE-RELATED ADVERSE EVENTS IN CANCER IMMUNOTHERAPY - PROJECT SUMMARY IMMUNE CHECKPOINT BLOCKADE (ICB) THERAPY HAS DEMONSTRATED | $693,716 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DYSREGULATION OF TET DIOXYGENASE FUNCTION AS A SOURCE OF ABERRANT TRANSPOSABLE ELEMENT EXPRESSION DURING HUMAN AGING - ABSTRACT IT IS WELL ESTABLISHED THAT AGIN | $639,037 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | PROTEOME-WIDE BASE EDITOR SCREENS TO ASSESS PHOSPHORYLATION SITE FUNCTIONALITY IN IMMUNOSENESCENCE - ABSTRACT WE OFTEN DEPICT SIGNALING PATHWAYS BY A DOZEN OR S | $566,215 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MATERNAL ANTIBODY-MEDIATED ENHANCEMENT OF DENGUE PATHOGENESIS - ABSTRACT DENGUE VIRUS (DENV) REPRESENTS A MAJOR THREAT TO GLOBAL HEALTH. HOWEVER, THE PRECISE RO | $551,334 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DEFINING INTERACTION QUANTITATIVE TRAIT LOCI (IQTLS) IN THE HUMAN GENOME | $494,100 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ELUCIDATING THE SIGNALING AND PROTEIN INTERACTION NETWORKS OF THE O-GLCNAC TRANSFERASE DURING EMBRYONIC STEM CELL STATE TRANSITIONS - PROJECT SUMMARY/ABSTRACT O | $457,500 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TRAINING IN IMMUNOLOGICAL MECHANISMS | $422,882 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | GENETIC STUDIES LINKING LSP1 FUNCTION IN T CELLS TO INFLAMMATORY BOWEL DISEASE - PROJECT SUMMARY/ABSTRACT INFLAMMATORY BOWEL DISEASES (IBD) CAUSE SUBSTANTIAL MO | $362,340 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FILOVIRUS NUCLEOCAPSID ASSEMBLY, CAUGHT IN THE ACT, BY IN SITU STRUCTURAL BIOLOGY - FILOVIRUSES EMERGE NEARLY ANNUALLY AND CAUSE HEMORRHAGIC FEVER WITH HIGH MOR | $228,750 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | WHAT IS THE HUMAN ANTIBODY RESPONSE TO MEASLES VIRUS VACCINATION? - PROJECT SUMMARY/ABSTRACT VACCINES ARE THE GREATEST BANG FOR OUR PUBLIC HEALTH BUCK, YET VACC | $221,888 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | UNDERSTANDING PH-DEPENDENT RECEPTOR UTILIZATION OF LASSA VIRUS - THE OLD-WORLD ARENAVIRUS LASSA (LASV) CAN CAUSE SEVERE HEMORRHAGIC LASSA FEVER (LF), WHICH IS A | $221,888 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ILLUMINATING LUJO VIRUS GLYCOPROTEIN STRUCTURE, RECEPTOR ENGAGEMENT AND NEUTRALIZING ANTIBODY EPITOPES - PROJECT SUMMARY THE MAMMARENAVIRUS GENUS OF THE ARENAVI | $221,888 |
| 2025 | National Institutes of Health | Grant or other assistance | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 | LINKING SPECIFIC PHOSPHORYLATION EVENTS TO DISTINCT TRANSCRIPTIONAL STATES - ABSTRACT: LINKING SPECIFIC PHOSPHORYLATION EVENTS TO DISTINCT TRANSCRIPTIONAL STATE | $221,544 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE ROLE OF ALTERNARIA FUNGAL SENSITIZATION IN ASTHMA PATHOGENESIS - PROJECT SUMMARY ALTERNARIA ALTERNATA (ALT) IS THE MOST COMMON OUTDOOR AIRBORNE FUNGUS FOUND | $175,000 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ROLES OF VACCINE PERTURBATIONS ON GERMINAL CENTER DYNAMICS - PROJECT SUMMARY/ABSTRACT HUMAN IMMUNODEFICIENCY VIRUS (HIV) LACKS A VACCINE DESPITE BEING A GLOBAL | $40,394 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DYNAMIC ANALYSIS OF BETA CELL ATTACKS IN RESPONSE TO VIRUS INFECTION IN HUMAN PANCREATIC SLICES - PROJECT SUMMARY TYPE 1 DIABETES (T1D) IS A CHRONIC AUTOIMMUNE | -$94,737 |
| 2024 | National Institutes of Health | Grant or other assistance | ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H) 93.384 | STRATEGIC HERPESVIRUS IMMUNE EVASION AND LATENCY DEFENSE (SHIELD) | $31,104,137 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HIPC DATA COORDINATING CENTER - PROJECT SUMMARY/ABSTRACT THE HUMAN IMMUNOLOGY PROJECT CONSORTIUM (HIPC) WAS FOUNDED IN 2010 TO CREATE A NETWORK OF INDEPENDENT C | $3,958,261 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | IGF::OT::IGF IMMUNE EPITOPE AND ANALYSIS PROGRAM | $3,734,837 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FUNCTIONAL AND DYSFUNCTIONAL HUMAN CD4 T CELL AND B CELL RESPONSES TO BACTERIA AND VIRUSES | $2,595,434 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HUMAN IMMUNE SIGNATURES OF DENGUE VIRUS AND MYCOBACTERIUM TUBERCULOSIS EXPOSURE IN INFECTION, DISEASE AND VACCINATION | $2,391,540 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPING COMPUTATIONAL MODELS TO PREDICT THE IMMUNE RESPONSE TO B. PERTUSSIS BOOSTER VACCINATION | $1,350,127 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | THE IDENTIFICATION AND VALIDATION OF EPITOPES CONSERVED IN VIRAL PATHOGEN FAMILIES WITH PANDEMIC POTENTIAL | $1,124,982 |
| 2024 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | IDENTIFICATION AND CHARACTERIZATION OF T CELL EPITOPES FROM BACTERIAL PATHOGENS CAUSING PNEUMONIA | $1,123,365 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TET ENZYMES AS GUARDIANS OF GENOME STABILITY | $1,098,000 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | A NOVEL STRATEGY FOR VACCINE-INDUCED PROTECTION AGAINST MATERNAL-TO-FETAL TRANSMISSION OF ZIKA VIRUS - PROJECT SUMMARY THE LONG-TERM GOAL OF THIS PROJECT IS TO | $894,640 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HIV MRNA VACCINE STRATEGIES FOR EFFICIENT PRIMING, DIVERSITY AND DURABILITY OF IMMUNE RESPONSES - SUMMARY CONVENTIONAL VACCINE STRATEGIES HAVE NOT INDUCED SUCCE | $892,826 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MAXIMIZING GERMINAL CENTERS AND SOMATIC HYPERMUTATION TO HIV ENV IMMUNOGENS - ABSTRACT WE PROPOSE THAT THE FEATURES OF GERMINAL CENTER BIOLOGY IMPORTANT FOR DEV | $882,023 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | BZIP PROTEINS, NFAT, AND LYMPHOCYTE GENE INDUCTION | $842,353 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE - ABSTRACT RECENT YEARS HAVE WITNESSED A DRAMATIC RISE IN INTEREST TOWARDS CANCER EPITOPES IN GENERAL, AND NEO | $813,113 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPMENT OF A REPLICON RNA-BASED VACCINE AGAINST DENGUE AND ZIKA - ABSTRACT THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP A DENGUE-ZIKA VACCINE THAT PROVI | $721,849 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE ROLE OF CYTOPLASMIC AND NUCLEAR THEMIS IN IMMATURE AND MATURE T CELLS | $688,446 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EPIGENETIC CONTROL OF FOXP3 EXPRESSION IN INDUCED T REGULATORY CELLS | $679,237 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | BIOACTIVE METABOLITES MODULATE IMMUNE-RELATED ADVERSE EVENTS IN CANCER IMMUNOTHERAPY - PROJECT SUMMARY IMMUNE CHECKPOINT BLOCKADE (ICB) THERAPY HAS DEMONSTRATED | $659,355 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SIGNAL TRANSDUCTION AND GENE INDUCTION IN T LYMPHOCYTES | $658,800 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DYSREGULATION OF TET DIOXYGENASE FUNCTION AS A SOURCE OF ABERRANT TRANSPOSABLE ELEMENT EXPRESSION DURING HUMAN AGING - ABSTRACT IT IS WELL ESTABLISHED THAT AGIN | $658,800 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | EXPLORING THE POTENTIAL OF TET INHIBITION IN CANCER IMMUNOTHERAPY | $576,850 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | PROTEOME-WIDE BASE EDITOR SCREENS TO ASSESS PHOSPHORYLATION SITE FUNCTIONALITY IN IMMUNOSENESCENCE - ABSTRACT WE OFTEN DEPICT SIGNALING PATHWAYS BY A DOZEN OR S | $573,738 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MATERNAL ANTIBODY-MEDIATED ENHANCEMENT OF DENGUE PATHOGENESIS - ABSTRACT DENGUE VIRUS (DENV) REPRESENTS A MAJOR THREAT TO GLOBAL HEALTH. HOWEVER, THE PRECISE RO | $568,385 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ELUCIDATING THE SIGNALING AND PROTEIN INTERACTION NETWORKS OF THE O-GLCNAC TRANSFERASE DURING EMBRYONIC STEM CELL STATE TRANSITIONS - PROJECT SUMMARY/ABSTRACT O | $546,933 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DEFINING INTERACTION QUANTITATIVE TRAIT LOCI (IQTLS) IN THE HUMAN GENOME | $515,251 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | GENETIC STUDIES LINKING LSP1 FUNCTION IN T CELLS TO INFLAMMATORY BOWEL DISEASE - PROJECT SUMMARY/ABSTRACT INFLAMMATORY BOWEL DISEASES (IBD) CAUSE SUBSTANTIAL MO | $386,496 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TRAINING IN IMMUNOLOGICAL MECHANISMS | $328,919 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | SARS-COV-2-REACTIVE TISSUE-RESIDENT MEMORY T CELLS IN HEALTHY AND CANCER SUBJECTS | $293,085 |
| 2024 | National Institutes of Health | Grant or other assistance | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 | LINKING SPECIFIC PHOSPHORYLATION EVENTS TO DISTINCT TRANSCRIPTIONAL STATES - ABSTRACT: LINKING SPECIFIC PHOSPHORYLATION EVENTS TO DISTINCT TRANSCRIPTIONAL STATE | $288,240 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FILOVIRUS NUCLEOCAPSID ASSEMBLY, CAUGHT IN THE ACT, BY IN SITU STRUCTURAL BIOLOGY - FILOVIRUSES EMERGE NEARLY ANNUALLY AND CAUSE HEMORRHAGIC FEVER WITH HIGH MOR | $274,500 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | UNDERSTANDING PH-DEPENDENT RECEPTOR UTILIZATION OF LASSA VIRUS - THE OLD-WORLD ARENAVIRUS LASSA (LASV) CAN CAUSE SEVERE HEMORRHAGIC LASSA FEVER (LF), WHICH IS A | $274,500 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | WHAT IS THE HUMAN ANTIBODY RESPONSE TO MEASLES VIRUS VACCINATION? - PROJECT SUMMARY/ABSTRACT VACCINES ARE THE GREATEST BANG FOR OUR PUBLIC HEALTH BUCK, YET VACC | $274,500 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EXPERIMENTAL IDENTIFICATION OF FUNCTIONAL GWAS VARIANTS LINKED TO COVID-19 SEVERITY IN IMMUNE CELLS - PROJECT SUMMARY/ABSTRACT THE CLINICAL PRESENTATION OF SARS | $274,500 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ILLUMINATING LUJO VIRUS GLYCOPROTEIN STRUCTURE, RECEPTOR ENGAGEMENT AND NEUTRALIZING ANTIBODY EPITOPES - PROJECT SUMMARY THE MAMMARENAVIRUS GENUS OF THE ARENAVI | $274,500 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | STRUCTURE OF THE SARS-COV-2 NUCLEOCAPSID: BUILDING BLOCK TO VIRAL CAPSID - SARS-COV-2, THE CAUSATIVE AGENT OF AN UNPRECEDENTED GLOBAL PANDEMIC, HAS JUST FOUR ST | $229,720 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DYNAMIC ANALYSIS OF BETA CELL ATTACKS IN RESPONSE TO VIRUS INFECTION IN HUMAN PANCREATIC SLICES - PROJECT SUMMARY TYPE 1 DIABETES (T1D) IS A CHRONIC AUTOIMMUNE | $228,750 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EPIGENOME-WIDE ASSOCIATION STUDY OF CHILDHOOD ASTHMA | -$2,352 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | LJI EPITOPE VALIDATION CENTER: CHARACTERIZATION OF EPITOPE-SPECIFIC T CELLS RESPONDING TO FOOD, FUNGAL AND INNER CITY ALLERGENS | -$54,968 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CONSORTIUM FOR IMMUNOTHERAPEUTICS AGAINST EMERGING VIRAL THREATS | $7,006,270 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HIPC DATA COORDINATING CENTER - PROJECT SUMMARY/ABSTRACT THE HUMAN IMMUNOLOGY PROJECT CONSORTIUM (HIPC) WAS FOUNDED IN 2010 TO CREATE A NETWORK OF INDEPENDENT C | $3,457,602 |
| 2023 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | IGF::OT::IGF IMMUNE EPITOPE AND ANALYSIS PROGRAM | $3,209,450 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FUNCTIONAL AND DYSFUNCTIONAL HUMAN CD4 T CELL AND B CELL RESPONSES TO BACTERIA AND VIRUSES | $2,713,421 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HUMAN IMMUNE SIGNATURES OF DENGUE VIRUS AND MYCOBACTERIUM TUBERCULOSIS EXPOSURE IN INFECTION, DISEASE AND VACCINATION | $2,391,540 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPING COMPUTATIONAL MODELS TO PREDICT THE IMMUNE RESPONSE TO B. PERTUSSIS BOOSTER VACCINATION | $1,350,127 |
| 2023 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE - ABSTRACT RECENT YEARS HAVE WITNESSED A DRAMATIC RISE IN INTEREST TOWARDS CANCER EPITOPES IN GENERAL, AND NEO | $1,205,850 |
| 2023 | National Institutes of Health | Contract | COMPUTER SYSTEMS DESIGN SERVICES 541512 | LARGE SCALE T CELL EPITOPE DISCOVERY | $1,157,223 |
| 2023 | National Institutes of Health | Grant or other assistance | BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), BIODEFENSE MEDICAL COUNTERMEASURE DEVELOPMENT 93.360 | SARS-COV-2-REACTIVE TISSUE-RESIDENT MEMORY T CELLS IN HEALTHY AND CANCER SUBJECTS | $1,130,292 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | RESEARCH RESOURCES: EPIGENOMIC AND TRANSCRIPTOMIC PROFILES OF HUMAN IMMUNE CELLS | $1,093,781 |
| 2023 | National Institutes of Health | Contract | COMPUTER SYSTEMS DESIGN SERVICES 541512 | LARGE SCALE T CELL EPITOPE DISCOVERY | $943,977 |
| 2023 | National Institutes of Health | Contract | COMPUTER SYSTEMS DESIGN SERVICES 541512 | LARGE SCALE T CELL EPITOPE DISCOVERY | $884,111 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MAXIMIZING GERMINAL CENTERS AND SOMATIC HYPERMUTATION TO HIV ENV IMMUNOGENS - ABSTRACT WE PROPOSE THAT THE FEATURES OF GERMINAL CENTER BIOLOGY IMPORTANT FOR DEV | $869,654 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | BZIP PROTEINS, NFAT, AND LYMPHOCYTE GENE INDUCTION | $842,353 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | IDENTIFYING MECHANISMS AND CORRELATES OF LONG-LASTING VACCINE-INDUCED IMMUNITY TO WHOOPING COUGH | $823,202 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPMENT OF A REPLICON RNA-BASED VACCINE AGAINST DENGUE AND ZIKA - ABSTRACT THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP A DENGUE-ZIKA VACCINE THAT PROVI | $721,849 |
| 2023 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DEFINING INTERACTION QUANTITATIVE TRAIT LOCI (IQTLS) IN THE HUMAN GENOME | $721,350 |
| 2023 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | BIOACTIVE METABOLITES MODULATE IMMUNE-RELATED ADVERSE EVENTS IN CANCER IMMUNOTHERAPY - PROJECT SUMMARY IMMUNE CHECKPOINT BLOCKADE (ICB) THERAPY HAS DEMONSTRATED | $706,097 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE ROLE OF CYTOPLASMIC AND NUCLEAR THEMIS IN IMMATURE AND MATURE T CELLS | $688,446 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SIGNAL TRANSDUCTION AND GENE INDUCTION IN T LYMPHOCYTES | $658,800 |
| 2023 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | EXPLORING THE POTENTIAL OF TET INHIBITION IN CANCER IMMUNOTHERAPY | $597,158 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MATERNAL ANTIBODY-MEDIATED ENHANCEMENT OF DENGUE PATHOGENESIS - ABSTRACT DENGUE VIRUS (DENV) REPRESENTS A MAJOR THREAT TO GLOBAL HEALTH. HOWEVER, THE PRECISE RO | $568,385 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CD4 T CELL CONTROL OF CYTOMEGALOVIRUS | $565,653 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EPIGENETIC CONTROL OF FOXP3 EXPRESSION IN INDUCED T REGULATORY CELLS | $549,000 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SPECIFICITY OF CD8 CELLS IN ISLETS FROM TYPE 1 DIABETES PATIENTS | $549,000 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE ROLE OF TRAIL IN IMMUNE CONTROL OF CYTOMEGALOVIRUS | $549,000 |
| 2023 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | A TREG CELL-INTRINSIC CTLA4-PKC-ETA SIGNALING PATHWAY MEDIATING CONTACT-DEPENDENT SUPPRESSION OF TUMOR IMMUNITY: A NOVEL TARGET FOR CANCER IMMUNOTHERAPY | $512,601 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ROLE OF A NOVEL INTERFERON RESPONSIVE T CELL SUBSET IN ALLERGY AND ASTHMA - DISEASE ASSOCIATED WITH ALLERGIES SUCH AS ASTHMA ARE A RISING HEALTH PROBLEM WITH NO | $457,500 |
| 2023 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ELUCIDATING THE SIGNALING AND PROTEIN INTERACTION NETWORKS OF THE O-GLCNAC TRANSFERASE DURING EMBRYONIC STEM CELL STATE TRANSITIONS - PROJECT SUMMARY/ABSTRACT O | $457,500 |
| 2023 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | EVALUATION OF T FOLLICULAR REGULATORY CELLS AS NOVEL CELLULAR TARGETS OF CANCER IMMUNOTHERAPY - PROJECT SUMMARY IMMUNE CHECKPOINT BLOCKADE (ICB) TARGETING CTLA- | $418,613 |
| 2023 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | GENETIC STUDIES LINKING LSP1 FUNCTION IN T CELLS TO INFLAMMATORY BOWEL DISEASE - PROJECT SUMMARY/ABSTRACT INFLAMMATORY BOWEL DISEASES (IBD) CAUSE SUBSTANTIAL MO | $402,600 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | STRUCTURE OF THE SARS-COV-2 NUCLEOCAPSID: BUILDING BLOCK TO VIRAL CAPSID - SARS-COV-2, THE CAUSATIVE AGENT OF AN UNPRECEDENTED GLOBAL PANDEMIC, HAS JUST FOUR ST | $285,857 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DYNAMIC ANALYSIS OF BETA CELL ATTACKS IN RESPONSE TO VIRUS INFECTION IN HUMAN PANCREATIC SLICES - PROJECT SUMMARY TYPE 1 DIABETES (T1D) IS A CHRONIC AUTOIMMUNE | $274,500 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | A NOVEL CD4+ T CELL SUBSET ASSOCIATED WITH ALLERGY PROTECTION - PROJECT SUMMARY DISEASE ASSOCIATED WITH ALLERGIES SUCH AS ASTHMA ARE A RISING HEALTH PROBLEM WIT | $274,500 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TRAINING IN IMMUNOLOGICAL MECHANISMS | $246,704 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EXPERIMENTAL IDENTIFICATION OF FUNCTIONAL GWAS VARIANTS LINKED TO COVID-19 SEVERITY IN IMMUNE CELLS - PROJECT SUMMARY/ABSTRACT THE CLINICAL PRESENTATION OF SARS | $228,750 |
| 2023 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | THE ROLE OF INTESTINAL EPITHELIAL CELLS IN THE GENERATION OF PROTECTIVE CD4 CYTOTOXIC T LYMPHOCYTES | -$1,509 |
| 2023 | Department of Veterans Affairs | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | HISTOLOGY SERVICE | -$8,331 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | RABIES VIRUS GLYCOPROTEIN STRUCTURE DETERMINATION AND RECEPTOR BINDING INTERACTIONS | -$8,560 |
| 2023 | Food and Drug Administration | Contract | ALL OTHER PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES 541990 | ANALYSES OF IMMUNE RESPONSES FROM PERTUSSIS IMMUNIZED BABOONS | -$41,236 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | IMMUNE REGULATION BY DEUBIQUITINATION | -$450,000 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CONSORTIUM FOR IMMUNOTHERAPEUTICS AGAINST EMERGING VIRAL THREATS | $7,020,842 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FUNCTIONAL AND DYSFUNCTIONAL HUMAN CD4 T CELL AND B CELL RESPONSES TO BACTERIA AND VIRUSES | $4,330,604 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | IGF::OT::IGF IMMUNE EPITOPE AND ANALYSIS PROGRAM | $3,440,531 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HIPC DATA COORDINATING CENTER - PROJECT SUMMARY/ABSTRACT THE HUMAN IMMUNOLOGY PROJECT CONSORTIUM (HIPC) WAS FOUNDED IN 2010 TO CREATE A NETWORK OF INDEPENDENT C | $3,421,630 |
| 2022 | National Institutes of Health | Grant or other assistance | LUNG DISEASES RESEARCH 93.838 | IMMUNE CELL INTERACTIONS IN ATHEROSCLEROSIS | $2,648,176 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HUMAN IMMUNE SIGNATURES OF DENGUE VIRUS AND MYCOBACTERIUM TUBERCULOSIS EXPOSURE IN INFECTION, DISEASE AND VACCINATION | $2,391,540 |
| 2022 | National Institutes of Health | Contract | COMPUTER SYSTEMS DESIGN SERVICES 541512 | LARGE SCALE T CELL EPITOPE DISCOVERY | $1,674,623 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPING COMPUTATIONAL MODELS TO PREDICT THE IMMUNE RESPONSE TO B. PERTUSSIS BOOSTER VACCINATION | $1,351,458 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | LJI EPITOPE VALIDATION CENTER: CHARACTERIZATION OF EPITOPE-SPECIFIC T CELLS RESPONDING TO FOOD, FUNGAL AND INNER CITY ALLERGENS | $1,153,559 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | RESEARCH RESOURCES: EPIGENOMIC AND TRANSCRIPTOMIC PROFILES OF HUMAN IMMUNE CELLS | $1,090,250 |
| 2022 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TET ENZYMES AS GUARDIANS OF GENOME STABILITY | $1,058,400 |
| 2022 | Centers for Disease Control and Prevention | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | BAA TOPIC 22.3 - SYSTEMIC ASSESSMENT OF IMMUNITY TO B. PERTUSSIS USING VALIDATED ASSAYS & DATA INTEGRATION | $1,049,692 |
| 2022 | National Institutes of Health | Contract | COMPUTER SYSTEMS DESIGN SERVICES 541512 | LARGE SCALE T CELL EPITOPE DISCOVERY | $952,615 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MAXIMIZING GERMINAL CENTERS AND SOMATIC HYPERMUTATION TO HIV ENV IMMUNOGENS - ABSTRACT WE PROPOSE THAT THE FEATURES OF GERMINAL CENTER BIOLOGY IMPORTANT FOR DEV | $883,119 |
| 2022 | National Institutes of Health | Contract | COMPUTER SYSTEMS DESIGN SERVICES 541512 | LARGE SCALE T CELL EPITOPE DISCOVERY | $879,506 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | BZIP PROTEINS, NFAT, AND LYMPHOCYTE GENE INDUCTION | $842,353 |
| 2022 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE - ABSTRACT RECENT YEARS HAVE WITNESSED A DRAMATIC RISE IN INTEREST TOWARDS CANCER EPITOPES IN GENERAL, AND NEO | $839,859 |
| 2022 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | STIMULATING NEO-ANTIGEN SPECIFIC T CELL RESPONSES IN HEAD AND NECK CANCERS | $838,091 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | IDENTIFYING MECHANISMS AND CORRELATES OF LONG-LASTING VACCINE-INDUCED IMMUNITY TO WHOOPING COUGH | $823,202 |
| 2022 | National Institutes of Health | Grant or other assistance | BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), BIODEFENSE MEDICAL COUNTERMEASURE DEVELOPMENT 93.360 | SARS-COV-2-REACTIVE TISSUE-RESIDENT MEMORY T CELLS IN HEALTHY AND CANCER SUBJECTS | $732,439 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MATERNAL ANTIBODY-MEDIATED ENHANCEMENT OF DENGUE PATHOGENESIS - ABSTRACT DENGUE VIRUS (DENV) REPRESENTS A MAJOR THREAT TO GLOBAL HEALTH. HOWEVER, THE PRECISE RO | $725,399 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | DEVELOPMENT OF A REPLICON RNA-BASED VACCINE AGAINST DENGUE AND ZIKA - ABSTRACT THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP A DENGUE-ZIKA VACCINE THAT PROVI | $712,699 |
| 2022 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | BIOACTIVE METABOLITES MODULATE IMMUNE-RELATED ADVERSE EVENTS IN CANCER IMMUNOTHERAPY - PROJECT SUMMARY IMMUNE CHECKPOINT BLOCKADE (ICB) THERAPY HAS DEMONSTRATED | $706,425 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | INTEGRATED FUNCTIONAL HISTOPATHOLOGY OF THE DIABETIC HUMAN PANCREAS | $699,000 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE ROLE OF CYTOPLASMIC AND NUCLEAR THEMIS IN IMMATURE AND MATURE T CELLS | $688,446 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HISTAMINE-RELEASING FACTOR OLIGOMERS IN FOOD ALLERGY | $634,331 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HOST NUTRIENTS PERMIT IMMUNE EVASION OF NKT CELL ANTI-BACTERIAL RESPONSES | $615,389 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CD4 T CELL CONTROL OF CYTOMEGALOVIRUS | $615,063 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE ROLE OF TRAIL IN IMMUNE CONTROL OF CYTOMEGALOVIRUS | $549,000 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EPIGENETIC CONTROL OF FOXP3 EXPRESSION IN INDUCED T REGULATORY CELLS | $549,000 |
| 2022 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | DEFINING INTERACTION QUANTITATIVE TRAIT LOCI (IQTLS) IN THE HUMAN GENOME | $546,811 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | SIGNAL TRANSDUCTION AND GENE INDUCTION IN T LYMPHOCYTES | $540,000 |
| 2022 | National Institutes of Health | Grant or other assistance | RESEARCH INFRASTRUCTURE PROGRAMS 93.351 | AUTOMATED MULTISCALE SUPER-RESOLUTION CONFOCAL MICROSCOPE - ABSTRACT THE LA JOLLA INSTITUTE FOR IMMUNOLOGY (LJI) IS A PREMIER IMMUNOLOGY RESEARCH INSTITUTE IN T | $514,425 |
| 2022 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | A TREG CELL-INTRINSIC CTLA4-PKC-ETA SIGNALING PATHWAY MEDIATING CONTACT-DEPENDENT SUPPRESSION OF TUMOR IMMUNITY: A NOVEL TARGET FOR CANCER IMMUNOTHERAPY | $512,601 |
| 2022 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | EXPLORING THE POTENTIAL OF TET INHIBITION IN CANCER IMMUNOTHERAPY | $492,576 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ROLE OF A NOVEL INTERFERON RESPONSIVE T CELL SUBSET IN ALLERGY AND ASTHMA - DISEASE ASSOCIATED WITH ALLERGIES SUCH AS ASTHMA ARE A RISING HEALTH PROBLEM WITH NO | $457,500 |
| 2022 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ELUCIDATING THE SIGNALING AND PROTEIN INTERACTION NETWORKS OF THE O-GLCNAC TRANSFERASE DURING EMBRYONIC STEM CELL STATE TRANSITIONS - PROJECT SUMMARY/ABSTRACT O | $457,500 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CD4 T CELL, GERMINAL CENTER, AND ANTIBODY RESPONSE DEFECTS IN RECURRENT TONSILLITIS | $450,000 |
| 2022 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | TWEAK AND SKIN INFLAMMATION | $392,040 |
| 2022 | National Institutes of Health | Grant or other assistance | ORAL DISEASES AND DISORDERS RESEARCH 93.121 | USING COMMON FUND DATASETS FOR PRIORITIZATION OF DISEASE-ASSOCIATED GENETIC VARIANTS - ABSTRACT GENOME-WIDE ASSOCIATION STUDIES (GWAS) HAVE HIGHLIGHTED THAT DIS | $366,000 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TRAINING IN IMMUNOLOGICAL MECHANISMS | $332,676 |
| 2022 | Food and Drug Administration | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | CONTRACT FOR THE ANALYSIS OF LYMPH NODE FINE NEEDLE ASPIRATES FROM 48 BABOONS VACCINATED WITH B. PERTUSSIS WHOLE CELL OR ACELLULAR VACCINES | $41,236 |
| 2022 | Department of Veterans Affairs | Contract | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) 541715 | DNA TESTING | $20,780 |
| 2022 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | THE ROLE OF INTESTINAL EPITHELIAL CELLS IN THE GENERATION OF PROTECTIVE CD4 CYTOTOXIC T LYMPHOCYTES | $13,866 |
| 2022 | Department of Veterans Affairs | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | PROCESS BIOLOGICAL SAMPLES | $3,921 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | GENETIC SCREENS FOR KEY TRANSCRIPTIONAL REGULATORS OF ANTIVIRAL T CELL IMMUNITY | $0 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | LIAI EPITOPE VALIDATION CENTER: CHARACTERIZATION OF ALLERGEN SPECIFIC T CELLS | $0 |
| 2022 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY 541711 | R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH) | -$3 |
| 2022 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETED THERAPEUTICS AGAINST FILOVIRAL HEMORRHAGIC FEVER | -$6,748 |
| 2022 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | SMALL MOLECULE METABOLITES AS PREDICTORS AND MEDIATORS OF IMMUNE CHECKPOINT INHIBITOR RESPONSE | -$9,535 |
| 2022 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | TUMOR SUPPRESSIVE FUNCTIONS OF TET PROTEINS IN B CELL MALIGNANCIES: ROLE OF G-QUADRUPLEX STRUCTURES | -$21,041 |
| 2021 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | FUNCTIONAL AND DYSFUNCTIONAL HUMAN CD4 T CELL AND B CELL RESPONSES TO BACTERIA AND VIRUSES | $9,083,840 |
| 2021 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | CONSORTIUM FOR IMMUNOTHERAPEUTICS AGAINST EMERGING VIRAL THREATS | $8,968,983 |
| 2021 | National Institutes of Health | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | IGF::OT::IGF IMMUNE EPITOPE AND ANALYSIS PROGRAM | $3,202,741 |
| 2021 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HUMAN IMMUNE SIGNATURES OF DENGUE VIRUS AND MYCOBACTERIUM TUBERCULOSIS EXPOSURE IN INFECTION, DISEASE AND VACCINATION | $3,014,062 |
State business registration
- LA JOLLA INSTITUTE FOR IMMUNOLOGY CA, Employee benefit plan sponsor (Form 5500), Filed for plan year 2025
The same business name in the same state, from the state’s official registry data.
Patents
2 US patents filed in the last 20 years.
- LA JOLLA INSTITUTE FOR IMMUNOLOGY 2 patents, 2023-01-10 to 2025-03-11 EXACT high confidence: identical full name and state
| Patent | Title | Granted | Source |
|---|---|---|---|
| US 12246097 | Nanoparticle vaccine adjuvant and methods of use thereof | 2025-03-11 | PVGPATDIS, file of 2026-04-10 |
| US 11547672 | Nanoparticle vaccine adjuvant and methods of use thereof | 2023-01-10 | PVGPATDIS, file of 2026-04-10 |
The newest patents of the PatentsView assignees above, matched to this record by name (and state).
Trademarks
4 US trademarks, 4 live.
- La Jolla Institute for Immunology 4 marks, CA EXACT high confidence: identical full name and state
| Mark | Serial | Filed | Status | Source |
|---|---|---|---|---|
| LA JOLLA INSTITUTE FOR IMMUNOLOGY | 88651960 | 2019-10-11 | Registered | TRTDXFAP, file of 2026-09-05 |
| LA JOLLA INSTITUTE FOR IMMUNOLOGY LIFE WITHOUT DISEASE. | 88651898 | 2019-10-11 | Registered | TRTDXFAP, file of 2025-05-14 |
| LA JOLLA INSTITUTE FOR IMMUNOLOGY | 88641623 | 2019-10-03 | Registered | TRTDXFAP, file of 2026-09-10 |
| LIFE WITHOUT DISEASE | 85878995 | 2013-03-18 | Registered and renewed | TRTYRAP, file of 2026-04-03 |
The newest marks of the trademark owners above, matched to this record by name (and state).
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | LA JOLLA INSTITUTE FOR IMMUNOLOGY | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
Matched by name (and state) or EIN only; a shared name is not proof of the same person or organization.
Comments